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Maintenance of plasma glucose concentration is highly important for normal body 
physiology. Glucose is under normal circumstances the only energy source for the 
brain. The brain is unable to store glucose and is therefore dependent on glucose 
derived from the circulation. In the control of glucose homeostasis, insulin is an 
important hormone. Insulin stimulates glucose uptake by tissues like skeletal muscle 
and adipose tissue, and inhibits glucose production by the liver. The extent of action 
of insulin on glucose uptake and glucose production is determined by tissue insulin 
sensitivity. Physiologically, insulin sensitivity can be influenced by many factors, like 
obesity, FFA concentrations, glucoregulatory hormones, etc. Pathophysiological 
changes in insulin sensitivity are seen in obesity and type II diabetes mellitus. 
The studies in this thesis were performed to investigate the role of feeding status 
in crosstalk with the gut and the brain in the modulation of insulin sensitivity. In this 
chapter, a brief review is given of the involved diseases, obesity and type II diabetes 
mellitus (section 2), and of regulation of glucose metabolism (section 3). In this latter 
part, glucose homeostasis, nutritional status, insulin resistance and therapies  for 
insulin resistance are discussed. In section 4, the current knowledge of gut-brain 
interactions and food intake is summarised. This chapter ends with the outline of the 
present thesis. 
 
2. Obesity and type II diabetes mellitus 
 
Evolution has provided humans with physiological mechanisms to survive times of 
scarcity of food. The purpose of these mechanisms is to conserve energy, seeking 
food in times of scarcity and storing energy in times of abundance. Hence, this 
system leads towards storage of fat and weight gain in conditions of caloric excess. 
During the last few decades, unique circumstances and lifestyle alterations have 
developed from an evolutionary perspective in industrialised countries. In contrast to 
previous eras there is plenty of food and physical activity is reduced. This 
maladaptive combination of genes to survive periods of scarcity and an environment 
with abundant dietary calories has led to an increased incidence of overweight and 
obesity. 
Overweight and obesity are commonly assessed by using body mass index (BMI), 
defined as the quotient of weight in kilograms and the square of height in meters 





Globally, obesity has reached epidemic proportions, with more than 1 billion 
overweight adults (more than 300 million are obese among them). Childhood obesity 
is already epidemic in some areas and on the rise in others. According to the US 
Surgeon General, in the USA the number of overweight children has doubled and the 
number of overweight adolescents has trebled since 1980 (1). Recent data show that 
in the Netherlands, 46.5% of the population is overweight and 10.9% of the 
population is obese. Dramatically increasing percentages of obese youngsters are 
seen as well (2). 
Obesity is a major risk factor for developing chronic diseases, including 
cardiovascular disease, hypertension and stroke, certain forms of cancer, and type II 
diabetes mellitus. Ninety percent of the patients with type II diabetes mellitus are 
obese or overweight. Type II diabetes mellitus now affects obese children even 
before puberty. Retinopathy, kidney failure, heart disease, neuropathy and foot 
diseases are major complications of diabetes. These complications decrease quality 
of life, and increase the risk for premature death. Diabetes mellitus is the sixth 
leading cause of death with 3.2 million deaths world-wide every year (1;3).  
 
3. Regulation of glucose metabolism 
1. Glucose homeostasis 
It is highly important for normal body physiology to keep a constant blood glucose 
level. As the brain has no endogenous glucose supply and is a major consumer of 
glucose, it is dependent on glucose derived from the circulation. Plasma glucose 
concentration is maintained within narrow limits by a fine balance between 
endogenous (hepatic) glucose production and peripheral glucose utilisation. During 
fasting, glucose is the obligatory fuel that provides more than 90% of energy needed 
for brain function (4;5). The liver produces this obligatory amount of glucose by 
glycogenolysis and gluconeogenesis (6). Glycogenolysis is the process of breakdown 
of glycogen via glucose-6-phosphate to free glucose, gluconeogenesis is the process 
of generating new molecules of glucose from intermediates derived from the 
catabolism of glycerol and some amino acids (7). Glucose is also taken up by 
peripheral tissues, like skeletal muscle, adipose tissue and heart tissue. A small 
amount of glucose can be stored in skeletal muscle and the liver, as the 
polysaccharide glycogen, to provide a reserve supply of energy. 
 Glucose balance is tightly regulated by the interaction of different regulatory 
mechanisms, such as the classical glucoregulatory hormones, like insulin, glucagon, 




production and stimulates glucose uptake in skeletal muscle and adipose tissue. 
Insulin inhibits gluconeogenesis by inhibiting the transcription of the main 
gluconeogenic enzyme, phosphoenolpyruvate caboxykinase and by increasing the 
transcription of the main glycolytic enzyme, pyruvate kinase (8) (9). In addition, 
insulin decreases hepatic uptake of precursor amino acids and their availability from 
muscle (10). Insulin stimulates glucose uptake by binding to insulin receptors in the 
plasma membrane of skeletal muscle or adipose tissue. This binding triggers a 
variety of signal transduction pathways, which ultimately results in fusion of glucose 
transporter-4 (GLUT-4) with the plasma membrane. The increased number of 
plasma-membrane glucose transporters causes a higher rate of glucose movement 
from the extracellular fluid into the cells (11). 
 In addition to these effects on peripheral tissues, insulin affects neuropeptides in 
the hypothalamus involved in regulating food intake and energy expenditure (see 
also paragraph ‘brain and glucose metabolism’). More than 140 years ago, Claude 
Bernard (12;13) punctured the fourth ventricle in rabbits, which resulted in glucosuria. 
Although these striking findings suggested a key role for the brain in glucose 
homeostasis, its importance was largely neglected after the discovery of insulin in 
1922. However, new findings have revived interest in the role played by the brain, in 
particular the hypothalamus, in both glucose metabolism and the mechanism linking 
obesity to type II diabetes mellitus (14;15). 
 
2. Nutritional status 
With regard to nutritional status, there are two functional states: the absorptive state, 
during which ingested nutrients are entering the blood from the gastrointestinal tract, 
and the postabsorptive state, during which the gastrointestinal tract is empty of 
nutrients and energy must be supplied by the body’s own stores. 
 During the absorptive state, glucose is the major energy source of the body. 
During this phase, glucose taken up by skeletal muscle is in part oxidised and in part 
stored as glycogen. In adipocytes, the most important fate of glucose in the 
absorptive state is the transformation to fat (triglycerides (TG)) for storage. The 
transformation of glucose to TG is called lipogenesis. The liver takes up glucose as 
well and stores it either as glycogen or transforms it to TG. Most of this liver-TG is 
secreted as very low density lipoproteins (VLDL) into the blood. However, de novo 
lipogenesis contributes to only ~5 percent of VLDL-TG, whereas the major part of 
VLDL-TG is derived from reesterification of fatty acids derived from adipose tissue. 
VLDL-TG are taken up by peripheral tissues depending on tissue specific activity of 




peripheral tissues, especially adipose tissue, for storage and in other tissues, like the 
heart, for oxidation. During the absorptive state insulin levels are increased, thereby 
stimulating glucose uptake and glycogen synthesis and inhibiting glucose production. 
Insulin also stimulates lipogenesis and inhibits lipolysis (catabolism of TG into 
glycerol and fatty acids) and VLDL production. In this way, insulin lowers plasma 
glucose levels and promotes the storage of FFA/TG in fat, liver and skeletal muscle. 
When the absorptive state ends, synthesis of glycogen and fat stops and net 
catabolism occurs.  
In the postabsorptive state and during prolonged fasting, the gastrointestinal tract 
is empty, resulting in cessation of glucose absorption from the intestine. However, 
glucose concentrations must be maintained within narrow limits to preserve normal 
functioning of the body. When glucose concentrations decrease to low values, 
alterations of neural activity ranging from slight impairment of mental function to 
coma and even death may occur (16). There are two ways to keep glucose 
concentrations at a constant level, stimulation of glucose production and inhibition of 
glucose uptake. During the postabsorptive state glucose is produced by the liver 
through glycogenolysis and gluconeogenesis (6). The increase in gluconeogenesis is 
facilitated by low insulin concentrations present during fasting. This also results in a 
decrease in glucose uptake by insulin dependent tissues such as skeletal muscle 
and adipose tissue. Consequently, glucose is available for non-insulin dependent 
tissues such as the brain (4;5). In addition, lipolysis (catabolism of TG into glycerol 
and fatty acids) increases in adipose tissue, resulting in increased release of fatty 
acids from adipose tissue, which can be used by muscle and other tissues for energy 
supply. The liver can transform these fatty acids into ketone bodies by β-oxidation, 
and release them into the blood or convert them in VLDL-TG (see above). During 
prolonged fasting, ketone bodies are an important energy source for many tissues, 
including the brain (5).  
 
3. Obesity, insulin resistance, and type II diabetes  
Energy intake, which the body derives from food, is required to match energy 
expenditure, necessary for physical activity and other body functions. When energy 
intake exceeds expenditure, energy is stored in the form of adipose tissue to be 
utilised in conditions of food scarcity or increased energy demand. Overweight and 
obesity are outcomes of long-term excess of energy intake relative to energy 
expenditure. Particularly fat and energy intake are strongly and positively associated 
with body weight gain. A high fat (energy-dense) diet is an independent risk factor for 











energy expenditure, which leads to energy deposition in form of adipose tissue, can 
be seen as an imbalance between fat deposition and fat oxidation. Fat oxidation 
occurs predominantly during the postabsorptive state, whereas fat deposition is 
stimulated during the absorptive state. Obesity is an important determinant of insulin 
resistance and represents the most important risk factor for the development of type 
II diabetes mellitus (18-20).  
Insulin resistance reflects a condition with reduced biological effects of insulin 
(21). Different tissues may have different tissue-specific sensitivities to the actions of 
insulin. As insulin normally inhibits endogenous glucose production, hepatic insulin 
resistance is characterised by diminished inhibition of glucose production by insulin. 
In peripheral tissues, especially skeletal muscle and adipose tissue, insulin 
resistance is characterised by decreased insulin-mediated glucose uptake. With 
regard to lipid metabolism, the inhibitory effects of insulin on lipolysis and VLDL 
production are decreased and insulin-mediated lipogenesis is also decreased. Both 
genetic and environmental factors, such as dietary habits, are involved in tissue-
specific insulin sensitivity. Up till now, with the exception of rare monogenic variants, 
the inherent susceptibility to type II diabetes mellitus is considered to be attributable 
to complex interacting genetic determinants.  
Insulin resistance is a major determinant of the pathophysiology of type II diabetes 
mellitus. Insulin resistance results in the inability of circulating insulin to properly 
suppress hepatic glucose production and to stimulate the disposition of glucose (and 
other metabolic fuels). This leads to progressive hyperglycaemia, and therefore more 
prolonged stimulation of pancreatic β-cells. When β-cell compensation ultimately 































The interaction between overweight and insulin resistance is complex and involves 
several epidemiological associations (figure 1). Briefly reviewed, these are: 
- Fat distribution: Patients with central adiposity have higher insulin levels and 
are more insulin resistant than subjects with similar weight but with a 
peripheral type of obesity (22-24).  
- Plasma FFA levels: The extent of (direct) exposure of liver and muscle cells 
to FFA concentrations might be involved in mediating tissue specific insulin 
resistance. For instance, experimental elevation of FFA induces insulin 
resistance (25-27). At the cellular level, FFA and their metabolic products can 
reduce insulin signalling in muscle and liver (27).  
- Ectopic triglyceride accumulation: TG content of skeletal muscle and liver 
correlates directly with insulin resistance (27-31). These observations suggest 
that accumulation of fat in liver and muscle tissue might (partly) mediate 
obesity-induced insulin resistance.  
- Adipokines: Another major mechanism linking obesity to insulin resistance is 
a group of peptides, made by fat cells that alter insulin sensitivity. Adiponectin 
has been shown to reduce insulin resistance and reduced levels of 
adiponectin are found in progressive obesity (32;33). Tumor necrosis factor-
alpha (TNFα), interleukin-6, resistin and leptin increase insulin resistance 
(34). Elevated levels of these adipocytokines are observed with obesity 
(34;35). Various adipose tissue beds produce different amounts of these 
peptides, perhaps adding to the regional differences in the contribution of 
these adipose depots to insulin resistance.  
- Hyperglycaemia: Hyperglycaemia itself is known to induce insulin resistance 
(36). This partially reversible phenomenon is known as glucose toxicity. In β-
cells, oxidative glucose metabolism will always lead to production of reactive 
oxygen species, normally detoxified by catalase and superoxide dismutase. 
Because these enzymes are present in low amounts in β-cells, 
hyperglycaemia can result in the production of large amounts of reactive 
oxygen species in β-cells, with subsequent damage to cellular components.   
- Number of insulin receptors, post-receptor signalling by insulin and synthesis 
and translocation of GLUT4: It is suspected that alterations in de expression 
and/or function of these factors underlie insulin resistance in obesity as well 
as in type II diabetes. Among the many molecules involved in the intracellular 
processing of the signal provided by insulin, insulin receptor substrate (IRS)-
2, the protein kinase B (PKB)-beta isoform and the forkhead transcription 




have provided strong evidence that dysfunction of these proteins results in 
insulin resistance in vivo (37;38).  
- Glucoregulatory hormones: Glucocorticoids (39), sex steroids (40), growth 
hormone (41), and catecholamines (42;43) influence tissue insulin sensitivity.   
- Oxidative stress and vascular reactivity: These factors have also been 
suggested to be involved in the development of insulin resistance (44-46). 
However, oxidative stress, vascular reactivity, inflammation and insulin 
resistance seem to be interrelated and more research is needed to elucidate 
this relationship.   
- Diurnal rhythms: It is recently shown in healthy humans that insulin sensitivity 
changes rhythmically during the day (47). 
 
4. Therapies for insulin resistance 
As the mechanisms underlying the development of insulin resistance are not clear, a 
therapy that directly targets these mechanisms does not exist. A major goal of 
therapeutic intervention in diabetes is to reduce circulating glucose levels. Lifestyle 
changes are the first step towards a reduced risk of developing diabetes or better 
prognosis for diabetes patients. Lifestyle changes are an ideal method of diabetes 
prevention because of its beneficial effects on cardiovascular risk factors as well as 
on other benefits related to weight loss and an improved diet (48). Weight loss in 
obese patients with diabetes can improve survival. In addition, exercise also 
improves insulin sensitivity by increasing glucose uptake into skeletal muscle (11). 
However, these interventions require a strong will as lifestyle modification has been 
difficult to maintain over a long term. Weight loss is not maintained once exercise or 
diet has been discontinued, and symptoms of diabetes will recur. Therefore 
pharmacological strategies are required in addition to exercise or diets. 
Oral hypoglycemic drugs, such as (combinations of) metformin, acarbose, 
sulfonylurea’s, thiazolidinediones, and anti-obesity agents (like orlistat) are currently 
used as pharmacological treatment for diabetes. However, none of these treatments 
is perfect. Recently, a meta-analysis was performed, in which studies were included 
that have investigated the effects of several different drug classes on type 2 diabetes 
incidence (48). Oral hypoglycemic medications and orlistat were the only drugs that 
had been studied in randomised controlled trials with diabetes incidence as the 
primary end point. The available evidence suggests that oral hypoglycemic drugs 
may reduce diabetes incidence compared with placebo. The adequately powered 




troglitazone, and orlistat. However, they concluded that the data are not definitive and 
that no single agent can currently be recommended for diabetes prevention (48). 
Interestingly, recent reports show that gastrointestinal hormones appear to have 
effects both on food intake and glucose metabolism (see next paragraph). Therefore, 
these hormones might be interesting for therapeutic goals in the battle against type II 
diabetes mellitus.  
 
4. Gut-brain axis 
 
1. Brain and food intake 
Food intake is largely regulated by the central nervous system.  
Lesion experiments in the 1950’s showed that lesions of the ventromedial nucleus 
resulted in uncontrollable 
hyperphagia and obesity, whereas 
lesions of the lateral hypothalamus 
resulted in anorexia and weight loss 
(49). These experiments were the 
basis of the early concepts of 
hypothalamic appetite regulation. 
Although these concepts were a 
gross oversimplification, the 
hypothalamus is still regarded as an 
important feeding center of the brain. 
The hypothalamus consists of 
several nuclei involved in regulating 
food intake, including the arcuate 
nucleus (ARC), the paraventricular 
nucleus (PVN), the lateral hypothalamic area (LHA), the ventromedial nucleus 
(VMH), and the dorsomedial nucleus (DMH). 
Located at the bottom of the hypothalamus, around the 3rd ventricle, the ARC can 
be found (see figure 2). ARC neurons are called ‘first-order’ neurons, because of 
their ‘direct’ contact with peripheral satiety factors. The ‘second-order’ neurons can 
be found in the PVN, LHA, VMH and DMH. Within the ARC, at least two populations 
of ‘first-order’ neurons controlling appetite are characterized: 1) neurons co-
expressing Agouti-related peptides (AgRP) and neuropeptide Y (NPY) and 2) 




Figure 2. Central command centers. Reprinted with 
permission from Marx, SCIENCE 299:846 (2003). 




alpha-melanocyte stimulating hormone (α-MSH). The first neuronal circuit 
(AgRP/NPY) stimulates food intake and the other neuronal circuit (POMC/α-MSH) 
inhibits food intake (50). There is direct interaction between the NPY/AgRP pathway 
and the POMC/α-MSH pathway (see figure 3). During fasting conditions, the 
expression of these neuropeptides is altered; fasting results in an increase in NPY 
and AgRP mRNA expression and 
a decrease of POMC mRNA 
expression levels in the 
hypothalamus (51). Together, 
during fasting, food intake is 
stimulated.  
Mutations disrupting these 
hypothalamic pathways cause 
obesity in rodents and humans. 
Examples are obese POMC-/- 
and MC4R-/- mice (52;53) and 
humans with POMC, MC4R and 
CART mutations which are associated with obesity (54-58). 
 
2. Brain and glucose metabolism 
The central nervous system is suggested to play a key role in the control of glucose 
metabolism via brain pathways that overlap with those controlling food intake and 
body weight (59). The brain is an insulin-sensitive organ. Insulin provides afferent 
input to the CNS regarding the sufficiency of body fat stores. Receptors for insulin 
are concentrated in hypothalamic areas. Intracerebroventricular administration of low 
doses of insulin reduces food intake and body weight (60). Insulin has been shown to 
increase POMC gene expression, that is normally decreased during fasting, and 
inhibit the expression of mRNA levels encoding the orexigenic peptide neuropeptide 
Y (NPY) that are normally increased in the ARC during fasting (61-63).    
Brain insulin action nowadays is hypothesised as a requirement for intact glucose 
homeostasis. Okamoto et al. showed that selective expression of insulin receptors 
reduces diabetes severity (64). Chronic blockade of hypothalamic insulin receptor 
signaling was shown to cause hepatic insulin resistance and to increase hepatic 
glucose production (65;66). In contrast, acute depletion of insulin receptors in the 
liver impaired downstream insulin signalling, but failed to alter the effect of 
physiological hyperinsulinemia on the rate of glucose production (67). The 
Figure 3. Anatomy  and regulation of the NPY and POMC 
system. Reprinted with permission from Cone, Nat 





importance of neuronal insulin signalling is further underlined by evidence that mice 
with neuron-specific insulin receptor deletion are overweight, insulin-resistant, and 
glucose-intolerant (68).  
 
3. Gastrointestinal hormones and food intake 
Hormones secreted from peripheral tissues bind to receptors located in the 
hypothalamus (see figure 3) (69;70). These hormones are secreted from the 
pancreas (like insulin), from adipose tissue (like leptin) or from the gastrointestinal 
tract. In this thesis we focus on the last group of hormones.  
Because of permeable blood brain barrier at the bottom of the ARC and the 
presence of these receptors in the ARC, the AgRP/NPY and POMC/CART neurons 
can be reached and influenced by these hormones (71). Gastrointestinal hormones 
may also act indirectly to influence the activity of afferent neuronal pathways and 
brain stem circuits, which in turn project to the arcuate nucleus (72;73). 
Via the hypothalamus these hormones are able to affect food intake (see figure 4). 
Extensive reviews have been written about gastrointestinal hormones and the 
regulation of food intake recently (69;74-76). Here, we will give an overview of these 
hormones and their effects on food intake.  
 
Cholecyctokinin (CCK), which is released from the upper small intestine (duodenal 
and jejunal mucose) by I cells (77) (78), was the first gastrointestinal hormone shown 
to decrease food intake. CCK is thought to interact with CCK-1 receptors on vagal 
sensory fibers, with the signal being relayed to the brainstem. Consistent with this 
notion, the anorectic effects of 
CCK can be eliminated by 
subdiaphragmatic vagotomy or 
selective damage to vagal afferent 
nerves. Likewise, lesions of the 
brainstem area that receives vagal 
sensory afferents, attenuate CCK-
elicited anorexia. Within the brain, 
recent data suggest that 
melanocortin-4 receptors (MC4) 
modulate CCK’s action (79-82). 
Peptide YY (PYY3-36) is released from L-cells of the distal gut upon feeding. Recently, 
there has been a lot of discussion about the effects of the gut hormone PYY3-36 on 
food intake (83). However, there is more or less consensus now that PYY3-36 
 
 
Figure 4. The gut-brain interaction in the regulation of 
appetite and body weight. Reprinted with permission 
from Hanusch-Enserer Eur J Clin Invest 35:425-430 




decreases food intake in both rodents (peripheral and central    administration) and 
humans (84-86). To inhibit feeding, PYY3-36 may act through the Y2 receptor, a 
putative inhibitory presynaptic receptor that is highly expressed on NPY neurons in 
the ARC. 
Glucagon Like Peptide 1 (GLP-1) is a proglucagon-derived hormone that is also 
secreted from the L-cells of the distal gut upon meals and is known to decrease food 
intake in rodents and humans (87;88). GLP-1 binds to the GLP-1 receptor, that is 
found in the periphery (gut and endocrine pancreas) and is widespread throughout 
the central nervous system. The anorectic actions of GLP-1 are probably mediated 
through both peripheral and central mechanisms. A population of neurons that 
synthesise GLP-1 is located in the brainstem and projects to hypothalamic and 
brainstem areas important in the control of energy homeostasis (89;90). GLP-1 is 
also known to affect glucose metabolism. Numerous studies have shown, that GLP-1 
can improve glucose-stimulated insulin secretion and lower fasting and postprandial 
blood glucose levels in individuals with type 2 diabetes (91;92). Therefore, there is a 
lot of interest in this peptide for therapeutic goals in type 2 diabetes mellitus. (93;94).  
Glucagon Like Peptide 2 (GLP-2) is another product from proglucagon, and is 
secreted in parallel with GLP-1 from the L-cells of the distal gut. When centrally 
applied, GLP-2 inhibits food intake (95), which study provides evidence that GLP-2 
serves as a neurotransmitter in a distinct ascending pathway linking visceroceptive 
neurons of the brainstem with a hypothalamic target. Recently, a few studies have 
been performed in which GLP-2 was peripherally administrated in humans. However, 
these three studies could not find effects of peripheral GLP-2 on appetite, energy 
intake or satiety (96-98). 
Oxyntomodulin (OXM) is a gastrointestinal hormone that is, just like GLP-1 and GLP-
2, a product of post-translational processing of preproglucagon and released from the 
L-cells in response to food ingestion and in proportion to meal calorie content 
(99;100). OXM inhibits food intake both in rodents and in humans after peripheral 
administration (101-103). It is currently unclear through which receptor OXM 
mediates its actions. There is evidence that circulating OXM could mediate its 
anorectic actions via direct interaction with the hypothalamus, activating POMC 
neurons within the ARC (103). 
Ghrelin, identified in 1999, and released from the X/A-like cells from the stomach, 
especially just before a meal (104), is, both in rodents and humans, the only peptide 
hormone found to stimulate appetite when administered peripherally (105-108). To 
enhance appetite, peripheral produced acylated ghrelin acts in the hypothalamus 




expression via activation of the growth hormone secretagogue receptor (GHS-R) 
(109-115).  
Since gastrointestinal hormones influence appetite and food intake in interaction with 
the brain, especially the ARC, and recent reports point to a central role of the brain in 
the regulation of insulin sensitivity, we hypothesised that gut-brain interactions might 
also be involved in the regulation of insulin sensitivity, independently of their effects 
on food intake and body weight. 
 
5. Outline of the present thesis 
 
The aim of this thesis was to gain more insight in the role of feeding status and gut-
brain interaction in the modulation of insulin sensitivity. There is growing evidence 
that neuropeptides which are situated in the hypothalamus, and gastrointestinal 
hormones which act on the hypothalamus, and are involved in regulating food intake, 
seem to be involved in regulating insulin sensitivity as well. Therefore, we first 
characterized the effects of feeding status itself on insulin sensitivity, and 
subsequently the effects of some of the signals for feeding status in the gut-brain 
axis, on insulin sensitivity. 
 
In chapter 2, we investigated the effect of fasting on insulin sensitivity in mice.  
During fasting FFA concentrations and liver TG content are increased. In obesity, 
increased FFA concentrations and excessive tissue TG storage are associated with 
tissue insulin resistance. The impact of fasting on tissue insulin sensitivity is 
unknown. Therefore, we studied the effects of 16 hr of fasting (prolonged fasting) 
versus 4 hr of fasting (postprandial state) on hepatic and muscle insulin sensitivity in 
wild-type mice in vivo in relation to tissue TG accumulation and changes in mRNA 
expression of transcription factors and related proteins involved in glucose and lipid 
metabolism.  
 
In chapter 3, the effects of a 2 week high fat diet on insulin sensitivity in relation to 
hypothalamic neuropeptides are presented. Studies in rats and dogs on a high fat 
diet show the induction of hepatic insulin resistance as an early event, followed by  
muscle insulin resistance later. The question was whether this primacy of hepatic 
insulin resistance in relation to changes in TG content is also present in mice.  
Secondly, the aim of this study was to evaluate whether the NPY/POMC circuitry is 




mRNA expression levels of these neuropeptides in the hypothalamus of mice after 2 
weeks of high fat diet. 
 
In chapter 4, we describe the effect of icv administration of MTII, a synthetic 
analogue of α-MSH, on insulin sensitivity. It is known that NPY can induce hepatic 
insulin resistance. However, whether the POMC pathway has effects on insulin 
sensitivity, independently of changes in food intake and body weight is not 
investigated. This study was performed to answer that question. 
  
In chapter 5 we evaluated the effects of acute administration of the gut-hormone 
PYY3-36 on insulin sensitivity. PYY3-36 inhibits NPY and activates POMC neuronal 
activity to inhibit food intake. As both NPY and the POMC pathway affect insulin 
sensitivity, the aim of this study was to evaluate whether PYY3-36 can affect insulin 
sensitivity independently of its effects on food intake. 
 
In chapter 6 we focussed on the effects of long-term administration of PYY3-36 on 
insulin sensitivity. A prerequisite for a drug against obesity and insulin resistance is 
that it has long-term effects. We administered PYY3-36 for 7 days, either continuously 
via subcutaneous mini-pumps or intermittent via daily subcutaneous injections to 
measure its long-term effects on insulin sensitivity. 
 
In chapter 7 we investigated whether ghrelin and des-ghrelin, produced by the 
stomach might affect insulin sensitivity in mice. Ghrelin promotes neuropeptide Y 
(NPY) gene expression and inhibits pro-opiomelanocortin (POMC)/αMSH expression 
via activation of the GHS-receptor and thereby stimulates food intake. Our question 
was whether ghrelin might affect insulin sensitivity. To detect a potential mechanism, 
we investigated whether GHRP-6, an agonist of the GHS-receptor can also influence 
insulin sensitivity. Des-ghrelin has not been seen as a bio-active hormone until 
recently. There are very recent publications that des-ghrelin might affect glucose 
production in hepatocytes. Therefore, the second aim of this study was to investigate 
the role of des-ghrelin in the regulation of insulin sensitivity. 
 
In chapter 8, the results of the above mentioned studies are summarised and put 
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Fasting readily induces hepatic steatosis. Hepatic steatosis is associated with 
hepatic insulin resistance. The purpose of the present study was to document 
the effects of 16 hours fasting in wildtype mice on insulin sensitivity in liver 
and skeletal muscle in relation to 1) tissue accumulation of triglycerides (TG’s) 
and 2) changes in mRNA expression of metabolically relevant genes. Sixteen 
hours of fasting did not show an effect on hepatic insulin sensitivity in terms of 
glucose production in the presence of increased hepatic triglyceride content. 
In muscle, however, fasting resulted in increased insulin sensitivity with 
increased muscle glucose uptake without changes in muscle triglyceride 
content. In liver, fasting resulted in increased mRNA expression of genes 
promoting gluconeogenesis and TG synthesis but in decreased mRNA 
expression of genes involved in glycogenolysis and fatty acid synthesis. In 
muscle, increased mRNA expression of genes promoting glucose uptake, as 
well as lipogenesis and β-oxidation was found. In conclusion, 16 hours fasting 
does not induce hepatic insulin resistance although it causes liver steatosis, 
whereas muscle insulin sensitivity increases without changes in muscle 
triglyceride content. Therefore, fasting induces differential changes in tissue-
specific insulin sensitivity and liver and muscle TG contents are unlikely to be 








Fasting increases hepatic triglycerides (TGs) in rodents (1). This fasting-induced 
hepatic steatosis results from repartitioning of FFAs, released from adipose tissue, to 
the liver. In the liver, FFAs can either be used for β-oxidation in mitochondria, or 
reesterified into TG. TG can be stored, or secreted as VLDL. In turn, TG-rich VLDL 
particles are lipolyzed by LPL and deliver FFAs to other tissues, like skeletal muscle 
(2), where FFAs are used for β-oxidation. If muscle FFA uptake exceeds β-oxidation, 
excessive TG storage will be the consequence (3).  
Evidence is accumulating indicating that accumulation of TG is involved in tissue-
specific insulin resistance. For instance, studies in transgenic mice with targeted 
disturbances in peripheral fatty acid/TG partitioning showed, that there is an inverse 
relationship between hepatic TG stores and hepatic insulin sensitivity (4;5). In 
muscle, TG accumulation is also associated with insulin resistance, characterized by 
a decrease in insulin-stimulated glucose uptake (6). There is a lot of evidence on the 
action of fatty acid derivatives as agonists and antagonists for nuclear transcription 
factors, such as peroxisome proliferator-activated receptors (PPARs) and sterol-
regulatory element binding proteins (SREBPs) (7;8). These transcription factors 
profoundly alter the expression of enzymes/proteins involved in glucose and lipid 
metabolism (8-13) and have interactions with hormones such as insulin (14;15). 
Therefore, these transcription factors could be molecular links between intracellular 
fatty acid/TG accumulation and insulin resistance. Because hepatic steatosis is 
associated with hepatic insulin resistance, we postulated that fasting also induces 
hepatic insulin resistance. The effects of fasting on muscle TG accumulation and 
insulin sensitivity have not been studied. Therefore, the aim of the present study was 
to evaluate the effects of 16 h of fasting on hepatic and muscle insulin sensitivity in 
wild-type mice in vivo in relation to 1) tissue TG accumulation and 2) changes in 
mRNA expression of transcription factors and related proteins involved in glucose 
and lipid metabolism.  
 
MATERIALS AND METHODS  
 
Animals 
Male, 12-16 week old, C57Bl/6 mice were used in all experiments. Mice were kept in 
a temperature- and humidity-controlled environment and had free access to standard 
mouse chow and water. Control mice were fasted 4 h with food withdrawn at 5:00 




PM (16 h fasted). All experiments were performed at 9:00 AM. All animal 
experiments were approved by the Animal Ethic Committee from the Leiden 
University Medical Center and Netherlands Organization for Applied Scientific 
Research (TNO) Prevention and Health (Leiden, The Netherlands). 
 
Hyperinsulimemic euglycemic clamp 
Hyperinsulinemic euglycemic clamps of the two experimental groups were performed 
side by side on the same day. The hyperinsulinemic euglycemic clamp was 
performed as described previously (4;16). In short, a continuous infusion of D-
[14C]glucose (0.3 µCi/kg/min; Amersham, Little Chalfont, UK) was started and blood 
samples were taken (after 60 and 80 minutes of tracer infusion) to determine basal 
glucose kinetics. Subsequently, a hyperinsulinemic study started with a bolus of 
insulin (100 mU/kg Actrapid; Novo Nordisk, Chartres, France) followed by continuous 
infusion of insulin (6.8 mU/h) and of D-[14C]glucose. A variable infusion of 12.5% D-
glucose (in PBS) solution was also started and adjusted to maintain blood glucose 
levels constant at ~8 mmol/l, measured via tail bleeding (Freestyle, TheraSense; 
Disetronic Medical Systems BV, Vianen, The Netherlands). During the last hour of 
the experiment, blood samples (75 µl) were taken every 20 minutes to determine 
plasma [14C]glucose and insulin concentrations. 
To estimate insulin-stimulated glucose uptake in individual tissues, 2-deoxy-D-
[3H]glucose (2-[3H]DG; Amersham) was administered as a bolus (1 µCi) 40 minutes 
before the end of the clamp procedure. 
After the last blood sample was taken, mice were killed and liver and muscle were 




Plasma levels of ketone bodies, glucose and free fatty acids were determined using 
commercially available kits (#310-A Sigma GPO-Trinder kit and #315-500; Sigma, 
St.Louis, MO; FFA; Wako Pure Chemical Industries, Osaka, Japan). Plasma insulin 
concentrations were measured by radio immunoassay using rat insulin standards 
(Sensitive Rat Insulin Assay; Linco Research, St.Charles, MO). For determination of 
plasma D-[14C]glucose, plasma was deproteinized with 20% trichloroacetic acid, dried 
to remove water, resuspended in demiwater and counted with scintillation fluid 
(Ultima Gold; Packard, Meridien, CT) on dual channels for separation of 14C and 3H, 
as described earlier (17). 
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Tissue analysis 
Liver and muscle samples were homogenized (~10% w/v) in water. Lipids were 
extracted according to Bligh and Dyer’s method (18). In short, a solution was made of 
each 200 µg sample of protein in 800 µl of water, then 3 ml methanol-chloroform 
(2:1) was added and mixed thoroughly, after which 500 µl of chloroform, 100 µl of 
internal standard, and 1 ml of demiwater were added. After centrifugation, the 
chloroform layer was collected and dried. The remaining pellet was dissolved in 50 µl 
chloroform and put on a high-performance TLC plate. With high-performance TLC 
analysis, TGs, cholesterol, and cholesteryl esters were separated. The amount of TG 
in the tissues was quantified by scanning the plates with a Hewlett-Packard Scanjet 
4c and by integration of the density using Tina® version 2.09 software (Raytest, 
Staubenhardt, Germany).  
For determination of tissue 2-DG uptake, the homogenate of muscle was boiled 
and the supernatant was subjected to an ion-exchange column to separate 2-DG-6-
phosphatase from 2-DG, as described previously (16;17;19). 
 
Calculations 
Under steady-state conditions for plasma glucose concentrations, the rate of glucose 
disappearance equals the rate of glucose appearance [body glucose uptake (BGU)]. 
The latter was calculated as the ratio of the rate of infusion of D-[14C]glucose 
(dpm/min) and the steady-state plasma [14C]glucose specific activity (dpm/µmol 
glucose). Hepatic glucose production (HGP) was calculated as the difference 
between the rate of glucose disappearance and the infusion rate of exogenous D-
glucose. 
The hepatic insulin sensitivity index was calculated as the ratio of the relative 
suppression of HGP during the hyperinsulinemic condition to the change in plasma 
insulin levels from basal to hyperinsulinemic conditions. The whole body insulin 
sensitivity index was calculated as the ratio of BGU to plasma insulin levels during 
hyperinsulinemic conditions.  
Muscle-specific tissue glucose uptake was calculated from tissue 2-DG content, 
which was expressed as percentage of 2-DG of the dosage per gram of tissue, as 
previously described (19). 
 
Real-time Polymerase Chain Reaction 
Real-time polymerase chain reaction (RT-PCR) was used to measure mRNA 





Table 1 Primer and probe sequences of genes used for mRNA quantification 
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coactivator-1 (PGC1), PPARγ, diacylglycerol acyltransferase 1 (DGAT1), DGAT2, 
SREBP1c, FAS, acyl-coA carboxylase (ACC) 1, and PPARα] and in liver 
[phosphoenolpyruvate carboxylase (PEPCK), glucose-6-phosphatase (G6P), 
glycogen phosphorylase (GP), PGC1, PPARγ, SREBP1c, FAS, ACC1, PPARα, 
DGAT1, and DGAT2] of mice after 4 and 16 h of starvation. Two other groups of 
mice, which were not subjected to a hyperinsulinemic clamp, were killed after 4 or 16 
h of fasting, and liver and skeletal muscle were taken out for further analysis. 
Muscle and liver were homogenized in 1,2 ml RNA-Bee (Tel-Test, Inc.) and total 
RNA was extracted according to Chomzcinsky and Sacchi (20). The amount of RNA 
was determined by spectrophotometry at a wavelength of 260nm. The quality was 
checked by the ratio of absorption at 260nm and absorption at 280nm. cDNA was 
obtained from total RNA.  
For RT-PCR, forward and reverse primers and TaqMan probe (table1) were 
designed from mouse-specific sequence data (Entrez, National Institutes of Health; 
and Ensembl, Sanger Institute) using computer software (Primer Express; Applied 
Biosystems). For each of the genes, a Basic Local Alignment Search Tool search 
was done to reveal that sequence homology was obtained only for the target gene. 
All TaqMan probes were 5’-6-carboxyfluorescein and 3’-BlackHoleQuencher-1 
(BHQ1) labeled, except for glyceraldehyde phosphate dehydrogenase (GAPDH) (5’-
VIC and 3’-BHQ1; Applied Biosystems) and cyclophiline (5’-TET and 3’-BHQ1). 
Each oligonucleotide set was optimized to determine the optimal primer 
concentrations and probe concentration and verify the efficiency of the amplification. 
PCR amplification was performed in a total reaction volume of 12.5 µl. The reaction 
mixture consisted of qPCR™ MasterMix (Eurogentec), the optimal primer and probe 
concentrations of target gene and the endogenous control, nuclease free water, and 
cDNA. An identical cycle profile was used for all genes: 50°C for 2 min, 95°C for 10 
min, followed by [95°C for 15 sec and 60°C for 1 min for 40 cycles.  
Data were analyzed using a comparative critical threshold (Ct) method in which 
the amount of target normalized to the amount of endogenous control 
(GAPDH/cyclophiline) and relative to the control sample is given by 2-∆∆Ct (Applied 
Biosystems). For each gene, all samples were run together allowing relative 






The data are presented as means ± SD. The data were analyzed using a non-
parametric Mann-Whitney U test for independent samples. Differences were 




Body weight and plasma parameters  
Body weight and basal and hyperinsulinemic plasma concentrations are shown in 
Table 2. Body weight was significantly lower in 16 h fasted mice compared with 
control mice (P<0.05). Plasma insulin and FFA concentrations were not significantly 
different between the groups, whereas basal plasma glucose concentrations were 
lower and plasma ketone bodies higher in 16 h fasted mice (P<0.01). During the 
hyperinsulinemic euglycemic clamp procedure, there were no differences in plasma 
glucose and FFA concentrations between the two groups, whereas insulin 
concentrations were lower in the 16 h fasted animals (P<0.01).   
 
HGP  
Basal HGP was not significantly 
different between the 16 h fasted 
mice and the control mice (38±7 
versus 43±9 µmol/kg/min, 
respectively). Liver insulin sensitivity 
index also was not significantly 
different between 16 h fasted and 
control mice (38±29 versus 25±11; 
ns), as seen in figure 1.  
 
Glucose uptake  
Basal BGU was not significantly 
different between the 16 h fasted 
mice and the control mice (38±7 
versus 43±9 µmol/kg/min, 
respectively). Interestingly, whole 
body insulin sensitivity index was 
higher in 16 h fasted compared with 




















Fig. 1.  Liver insulin sensitivity index in 16h fasted
and control mice. Data are means ± SD for at least 9

























Fig. 2.  Whole-body insulin sensitivity index in 16 h
fasted and control mice. Data are means ± SD for at
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P<0.01), reflecting increased whole body insulin sensitivity after 16 h of fasting (figure 
2).  
Muscle-specific glucose uptake was 
significantly higher under 
hyperinsulinemic conditions in 16 h 
fasted compared with control mice 
(4.0±2.6 % versus 1.3 ± 0.2% glucose 
uptake/ g tissue, P<0.01) (figure 3).  
 
  Tissue lipid levels  
Hepatic TG content was 6-fold higher 
in 16 h fasted mice compared with 
control mice (71±19 versus 12±7 
µg/mg protein, P<0.01), whereas 
muscle TG content did not differ 
between the two groups (25±7 
versus 28±13 µg/mg protein; ns) 
(figure 4). 
 
mRNA expression levels 
Hepatic mRNA expression levels of transcription factors and related proteins involved 
in gluconeogenesis and in TG synthesis increased during 16 h of fasting, whereas 
mRNA expression levels of transcription factors and related proteins involved in 
glycogenolysis and fatty acid synthesis decreased. The expression levels of G6P and 
PPARα mRNA were not significantly different (table 3a).  
Muscle mRNA expression levels of transcription factors and related proteins 
involved in glucose uptake, fatty acid synthesis, TG synthesis and β-oxidation 
increased during 16 h of fasting, whereas SREBP1c (which has a role as a sensor of 




This study indicates that fasting does not result in changes in hepatic insulin 
sensitivity with regard to HGP in vivo. However, fasting increases muscle insulin 
sensitivity in vivo, reflected by an increased ability of insulin to stimulate muscle 

























Fig. 3. Muscle-specific glucose uptake under
hyperinsulinemic conditions in 16 h fasted and
control mice. Data are means ± SD for at least






















Fig. 4. TG content determined in liver and skeletal
muscle of 16h fasted and control mice. Data are
means ± SD for at least 6 animals per group. *p < 0.01




changes in insulin 
sensitivity. 
Moreover, the 
increase in muscle insulin 
sensitivity occurred 
without changes in 
muscle TG content. 
Therefore, changes in 
liver and muscle TG 
content are unlikely to be 
involved in changes in 
insulin sensitivity during  
conditions of fasting. 
Studies in transgenic 
mice with targeted 
disturbances in peripheral 
fatty acid/TG distribution 
showed that there 
appears to be an inverse 
dose-effect relationship 
between hepatic TG 
stores and hepatic insulin 
sensitivity (4;5). However, 
it does not seem possible 
to expand this theory to 
cases of fasting and 
fasting-induced hepatic 
steatosis. 
The increase in muscle 
insulin sensitivity during 
fasting is a new and 
interesting finding. 
Table 3. mRNA expression levels of different proteins in liver (a) and 
skeletal muscle (b) of control (n=4) and 16h (n=4) fasted mice. 
mRNA of control 16h 
   
Glucose uptake   
GLUT4 100 ± 2 % 157 ± 12% ** 
PGC1 100 ± 17% 166 ± 36 % * 
   
Nutritional status   
SREBP1c 100 ± 8 % 3 ± 0% ** 
   
Fatty acid synthesis   
FAS  100 ±10 % 123 ± 8 % * 
ACC1 100 ± 26 % 194 ± 35 % ** 
   
TG synthesis   
PPARgamma 100 ± 1 % 364 ± 12 % ** 
DGAT1 100 ± 12 % 193 ± 15 % ** 
DGAT2 100 ± 4 % 270 ± 20 % ** 
   
ß-oxidation   
PPARalpha 100 ± 7 % 278 ± 48% ** 
Values are expressed as means ±SD. *p<0.05 compared to control mice, **p<0.01 
compared to control mice 
mRNA of control 16h fasting 
   
Glucose production   
G6P 100 ± 7 % 138 ± 23 % 
PEPCK 100 ± 6 % 184 ± 9%** 
GP 100 ± 6 % 59 ± 1 % ** 
PGC1 100 ± 10% 380 ± 32 %** 
   
Fatty acid synthesis   
SREBP1c 100 ± 12 % 34 ± 1%** 
FAS  100 ± 11 % 12 ± 1 %** 
ACC1 100 ± 14 % 21 ±1 %** 
   
TG synthesis   
PPARgamma 100 ± 9 % 179 ± 4 %** 
DGAT1 100 ± 1 % 269 ± 6 %** 
DGAT2 100 ± 7% 113 ± 4 %* 
   
ß-oxidation   


























































































































































































































































































































































































































































Previous studies showed an inverse relationship between intramuscular TG content 
and insulin action (21;22). However, because we observed an increase in muscle 
insulin sensitivity without changes in muscle TG content, it is unlikely that changes in 
muscle TG play a role in the increased muscle-specific insulin sensitivity during 
fasting.  
During the hyperinsulinemic period of the clamp procedure, we observed 
significantly lower insulin concentrations in 16 h fasted mice compared with control 
mice. As both groups received the same amount of insulin during hyperinsulinemic 
conditions by infusion, this difference suggests an increased insulin clearance during 
fasting. Because of this difference, we corrected the data on insulin sensitivity for the 
insulin concentrations. 
Another purpose of the present study was to relate the observed in vivo metabolic 
changes to changes in the transcriptional regulation of genes involved in glucose 
metabolism, lipogenesis and β-oxidation in liver and muscle. In the liver, there were 
changes in expression of regulatory transcription factors favouring gluconeogenesis, 
β-oxidation and TG synthesis, with negative effects on glycogenolysis and fatty acid 
synthesis. Total HGP is the sum of glycogenolysis and gluconeogenesis. Liver 
glycogen stores are limited; consequently, during starvation the relative contribution 
of gluconeogenesis to total glucose production increases, whereas that of 
glycogenolysis decreases (23). PGC1 promotes gluconeogenesis by stimulation of 
PEPCK (24;25). Our results document a significant increase in the expression of 
PGC1 and PEPCK. GP is an enzyme involved in glycogenolysis, and its expression 
is decreased. G6P is involved in glucose production, with sources from both 
gluconeogenesis and glycogenolysis. The expression of G6P is not significantly 
altered by fasting, which seems to reflect the absence of changes in HGP in 16 h 
fasted compared with control mice. 
Our study showed a reduced expression level of SREBP1c. This decrease in 
SREBP1c mRNA during fasting is in accordance with findings of others in mouse 
liver (26). Hepatic expression levels of enzymes involved in fatty acid synthesis (FAS 
and ACC1) decreased during fasting. The expression of these enzymes is stimulated 
by SREBP1c (27). Although this was not reported in mice before, these findings are 
in accordance with those of Hillgartner, Charron, and Chesnut (28) in fasted 
chickens. Because a decrease in expression of SREBP1c, FAS and ACC1 during 16 
h of fasting results in decreased suppression of gluconeogenesis and reduced fatty 
acid synthesis, leaving pyruvate as a substrate for gluconeogenesis, these changes 
seem to be of physiological importance in the adaptive response of glucose and lipid 
metabolism to fasting.  
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The observed increase in liver TG accumulation in our study is in agreement with 
the observed increase of hepatic mRNA expression levels of PPARγ and of DGAT1 
and DGAT2, all three favoring hepatic TG synthesis (29). The increase in hepatic 
PPARγ is in line with findings of others (26;29;30). 
PPARα, which is known as ‘the fasting gene’, controls the expression of numerous 
genes related to lipid metabolism in the liver, including genes involved in β-oxidation, 
fatty acid uptake, and transport. Therefore, it is surprising that PPARα mRNA was 
not increased after 16 h of fasting, whereas this was found by others in wild-type 
mice (9). Because these mice had another background (SV129), and others found a 
decrease in PPARα mRNA after 48 and 72 h of fasting in wild-type mice (1) with the 
same background as our mice (C57Bl6), it seems likely that these differences in 
background explain this discrepancy.  
In muscle, RT-PCR results demonstrate that fasting-induced expression of genes 
and enzymes favouring glucose uptake. mRNA expression levels of PGC1 and 
GLUT4 were increased after 16 h of fasting. PGC1 can control the level of 
endogenous GLUT4 gene expression in multinucleate myotubes via coactivating 
MEF2C (31). Moreover, Hammerstedt et al. (32) showed a high correlation (r=0.91) 
between GLUT4 mRNA and PGC1 mRNA in human skeletal muscle. Therefore, our 
findings support their hypothesis that PGC1 is associated with increased GLUT4 
expression and insulin sensitivity.  
The observed decrease in muscle SREBP1c mRNA in our study is in agreement 
with recently published results (33). These studies found a decrease in SREBP1c 
mRNA in different rat muscle types that was related to the duration of fasting and 
consistent with a role for SREBP1c as a sensor of nutritional status in skeletal 
muscle. Although SREBP1c stimulates the expression of genes involved in lipid 
metabolism (such as FAS, ACC1) in tissues like the liver, not much is known about 
the regulatory role of SREBP1c in skeletal muscle. Because our study shows an 
increase in FAS and ACC1 mRNA during 16 h of fasting but decreased expression of 
SREBP1c, our data imply that muscle FAS and ACC1 are not stimulated by 
SREBP1c.  
The mRNA expression levels of PPARγ, another lipogenesis-promoting 
transcription factor in skeletal muscle, strongly increased during 16 h of fasting. This 
contrasts with a previous study (34), which found no alterations of PPARγ mRNA 
expression level during fasting in rat skeletal muscle. However, these rats were 
fasted for 46 h, whereas our mice were fasted for only 16 h. Because mRNA 




(35), were significantly increased after fasting in the absence of muscle TG 
accumulation in this period, it can be speculated that prolonged fasting will be 
accompanied by muscle TG accumulation.  
In the present study, PPARα mRNA, which is involved in β-oxidation, was 
increased after fasting. This is in agreement with a recent finding (36) showing 
increased muscle glucose uptake in mice treated with a PPARα agonist (WY14,643).  
In conclusion, 16 h of fasting in wild-type mice results in hepatic steatosis without 
changes in hepatic insulin sensitivity. In muscle, however, 16 h of fasting increased 
insulin sensitivity without changes in muscle TG content. Therefore, fasting induces 
differential changes in tissue-specific insulin sensitivity. In addition, changes in liver 
and muscle TG content are unlikely to be involved in changes in insulin sensitivity 
during fasting. 
 
This study was supported by the Netherlands Organization for Scientific Research (grants 907-00-002 
and 903-39-291) and was conducted in the framework of the Leiden Center for Cardiovascular 
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High fat diet induced hepatic insulin resistance is not related 
to changes in hypothalamic mRNA expression of NPY, AgRP, 
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The hypothalamic circuitry, apart from its impact on food intake, modulates 
insulin sensitivity to adapt metabolic conditions in the face of environmental 
fluctuations in nutrient availability. The purpose of the present study was to 
investigate the effects of 2 weeks high fat feeding in wildtype mice on (1) 
insulin sensitivity and triglyceride accumulation in liver and muscle in relation 
to (2) mRNA expression levels of Neuropeptide Y (NPY), Agouti-related protein 
(AgRP), pro-opiomelanocortin (POMC), and cocaine- and amphetamine-
regulated transcript (CART) in the hypothalamus. Two weeks of high fat 
feeding induced hepatic insulin resistance in the presence of increased hepatic 
triglyceride accumulation. In muscle, however, 2 weeks of high fat feeding did 
not result in changes in insulin sensitivity or in triglyceride content. mRNA 
expression levels of NPY, AgRP, POMC, and CART in the hypothalamus were 
not different between the groups. This study shows that 2 weeks of high fat 
feeding in mice does not affect mRNA expression levels of NPY, AgRP, POMC 
or CART, in the whole hypothalamus, despite induction of hepatic, but not 
peripheral, insulin resistance. Therefore, a major physiological role of these 
neuroendocrine factors in the induction of hepatic insulin resistance during a 








High fat (HF) diet is associated with the development of hepatic and muscle insulin 
resistance and the induction of liver steatosis and muscle triglyceride accumulation in 
rodents and humans. The induction of hepatic insulin resistance is an early event, 
whereas the indication of muscle insulin resistance occurs later in rats and dogs fed 
a HF diet for 3-12 weeks (11,12). The change in time of hepatic and peripheral 
insulin sensitivity during high fat feeding in mice has not been reported so far.  
The hypothalamic arcuate circuitry, apart from its impact on food intake, 
modulates insulin sensitivity to adapt metabolic conditions in the face of 
environmental fluctuations in nutrient availability. Two types of neurons in the 
hypothalamus are of major importance for the control of these processes: neurons 
co-expressing neuropeptide Y (NPY) and Agouti-related protein (AgRP), and neurons 
co-expressing pro-opiomelanocortin (POMC), the molecular precursor of alpha-
melanocyte stimulating hormone (α-MSH) and cocaine- and amphetamine-regulated 
transcript (CART) (8). These neuropeptides exert opposing effects on food intake and 
fuel homeostasis. We, and others, recently showed that, independent of its 
stimulating effect on food intake, NPY is also involved in controlling insulin action in 
peripheral tissues. Intracerebroventricular (icv) infusion of NPY induces hepatic 
insulin resistance in mice and rats (15,23). Conversely, subchronic (7 days) icv 
infusion of α-MSH enhances peripheral and hepatic insulin sensitivity in rats through 
stimulation of the melanocortin-3/4 receptor (16). These observations suggest that 
the balance between NPY/AgRP and POMC/CART neuronal activity may be a 
determinant of peripheral and hepatic insulin sensitivity. 
To explore a potential physiological relationship between the arcuate NPY/POMC 
circuitry and the development of tissue specific insulin resistance during a HF diet, 
we studied the effects of 2 weeks HF feeding in wildtype mice on (1) insulin 
sensitivity and TG accumulation in liver and muscle in relation to (2) mRNA 
expression levels of NPY, AgRP, POMC, and CART in the whole hypothalamus. 
 
MATERIAL AND METHODS  
 
Animals 
Male, 12-16 weeks old, C57Bl/6 mice were used in all experiments. Mice were kept 
in a temperature- and humidity controlled environment and had free access to food 




free access to standard chow diet whereas the experimental group had a high fat diet 
(21.5 wt.% fat or 43 energy% fat; saturated bovine fat) (Hope Farms, Woerden, the 
Netherlands) ad libitum. Before the experiments mice were fasted 4 h (postprandial) 
with food withdrawn at 05:00 h a.m., in order to exclude interfering effects of glucose 
uptake from the gastrointestinal tract. All experiments were performed at 09:00 h 
a.m. All animal experiments were approved by the Animal Ethic Committee from the 
Leiden University Medical Center and TNO-Prevention and Health, Leiden, the 
Netherlands. 
 
Hyperinsulinemic euglycemic clamp study 
The hyperinsulinemic euglycemic clamp study was performed as published earlier 
(7,22,24). In short, a continuous infusion of D-14C glucose, 0.3 µCi/kg.min, 
(Amersham, Little Chalfont, UK) alone was started and blood samples were taken to 
determine basal glucose parameters. The hyperinsulinemic study started with a bolus 
(100 mU/kg, Actrapid, Novo Nordisk, Bagsvaerd, Denmark) followed by continuous 
infusion of insulin (6.8 mU/h) and of D-14C glucose. A variable infusion of 12.5% D-
glucose (in PBS) solution was adjusted to maintain euglycemia, as measured via 
tailbleeding (Freestyle, TheraSense, Disetronic Medical Systems BV, Vianen, the 
Netherlands). Blood samples (75µl) were taken when glucose levels in the blood 
were stable for determination of plasma [14C]glucose and insulin concentrations. To 
estimate insulin-stimulated glucose uptake in individual tissues, 2-deoxy-D-
[3H]glucose (2-[3H]DG; Amersham, Little Chalfont, UK) was administered as a bolus 
(1µCi), 40 minutes before the end of the clamp. After the last blood sample was 
taken, mice were sacrificed and liver and muscle were taken out, immediately frozen 
using liquid N2 and stored at -20°C until further analysis. For the determination of 
plasma D-14C glucose, plasma was deproteinized with 20% trichloroacetic acid, dried 
to remove water, resuspended in demi-water and counted with scintillation fluid 
(Ultima Gold, Packard, Meridien, CT, USA) on dual channels for separation of 14C 
and 3H, as described earlier (7,22,24). 
 
Plasma parameters 
Plasma glucose, free fatty acid and insulin levels were determined using 
commercially available kits (Sigma, St.Louis, MO; Wako Pure Chemical Industries, 
Osaka, Japan; Mercodia, Uppsala, Sweden, respectively).  
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Tissue analysis 
Liver and muscle samples were homogenized (~10% wet w/v) in H2O. Lipids were 
extracted according to Bligh and Dyer’s method (2). In short, a solution was made of 
each sample of 200 µg protein in 800 µl H2O, then 3 ml methanol/chloroform (2:1) 
was added and mixed thoroughly, after which 500 µl of chloroform, 100 µl internal 
standard and 1 ml demi-water were added. After centrifugation the chloroform layer 
was collected and dried. The remaining pellet was dissolved in 50µl chloroform and 
put on a HPTLC plate. The amount of TG in the tissues was quantified by scanning 
the plates with a Hewlett Packard Scanjet 4c and by integration of the density using 
Tina® version 2.09 software (Raytest, Staubenhardt, Germany).  
For determination of tissue 2-DG uptake, the homogenate of muscle was boiled 
and the supernatant was subjected to an ion-exchange column to separate 2-DG-6-P 
from 2-DG as described previously (7,18,22,24). 
 
Calculations 
Under steady-state conditions for plasma glucose concentrations, the rate of glucose 
disappearance equals the rate of glucose appearance (Ra; i.e. endogenous glucose 
production plus exogenous D-glucose infusion). The latter was calculated as the ratio 
of the rate of infusion of D-14C glucose (dpm/min) and the steady-state plasma 
[14C]glucose specific activity (dpm/µmol glucose). Hepatic glucose production (HPG) 
was calculated as the difference between Ra and the infusion rate of exogenous D-
glucose. Muscle tissue specific glucose uptake was calculated from tissue 2-DG 
content, which was expressed as percent of 2-DG of the dosage per gram of tissue, 
as described previously (18). 
 
Extraction of hypothalamus 
Two other groups of mice fed on chow or 2 weeks HF diet were, after 4 hours fasting, 
sacrificed at 9 a.m. by cervical dislocation. After death, the brain was dissected from 
the skull. A region bordered dorsally by the thalamus, rostrally by the optic chiasm, 
laterally by the internal capsule, and caudally by the mammillary bodies was excised, 
as described previously (9). Hypothalami removed were immediately frozen in liquid 
nitrogen.  
 
Real Time Polymerase Chain Reaction (RT-PCR) 
A real time polymerase chain reaction (RT-PCR) was used to measure 
NPY/AgRP/POMC/CART mRNA expression levels in the hypothalamus of mice after 




(Tel-Test, Inc, Texas, US) and total RNA was extracted according to Chomzcinsky 
and Sacchi (5). The amount of RNA was determined by spectrophotometry (ND-1000 
spectrophotometer, Nanodrop®) at a wavelength of 260 nm. The quality was 
checked by the ratio of the absorption at 260 nm and the absorption at 280 nm. 
Complementary DNA (cDNA) was obtained of total RNA.  
For RT-PCR, forward and reverse primers were designed from mice specific 
sequence data (Entrez, National Institutes of Health; and Ensembl, Sanger Institute) 
using computer software (Primer Express, Applied Biosystems). For each of the 
genes a Blast Search was done to reveal that sequence homology was obtained only 
for the target gene. Forward and reverse primers of NPY 
(5’CGCTCTGCGACACTACATCAA3’; 5’GGGCTGGATCTCTTGCCAT3’), AgRP (5’ 
GGTGCTAGATCCACAGAACCG 3’; 5’ CCAAGCAGGACTCGTGCAG 3’), POMC (5’ 
CGAGGCCTTTCCCCTAGAGT 3’; 5’ CCAGGACTTGCTCCAAGCC 3’), and CART 
(5’ TGGATGATGCGTCCCATGA 3’; 5’ CGGAATGCGTTTACTCTTGAGC 3’) were 
used. Neuron-specific enolase (NSE) (5’ ACGTGGTTCCATTTCAAGATGAC 3’; 5’ 
CGAGCTTCAGTTAGTGCACCAA 3’) and hypoxanthine phosphoribosyltransferase 
(HPRT) (5’ GCTCGAGATGTCATGAAGGAGAT 3’; 5’ 
AAAGAACTTATAGCCCCCCTTGA 3’) were used as housekeeping genes.  
PCR amplification was performed in a total reaction volume of 20 µl. The reaction 
mixture consisted of SybrGreen mix (Applied Biosystems, United Kingdom), forward 
and reverse primers, nuclease free water and cDNA. An identical cycle profile was 
used for all genes: 50°C for 2 min + 95°C for 10 min + [95°C for 15 sec + 60°C for 1 
min] * 50 cycles. Specificity of NPY, AgRP, POMC, CART, NSE and HPRT 
amplifications was confirmed by analyzing the dissociation curves of the target 
amplicon. Data were analysed using a comparative critical threshold method as 
described previously (7). 
 
Statistical analysis 
Data are presented as means ± standard deviation. Data were analysed using a non-
parametric Mann-Whitney U-test for independent samples. Differences were 




Body weight and plasma parameters 
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Two weeks of high fat diet did not lead to differences in body weight, plasma glucose, 
insulin or FFA levels compared to chow-fed littermates. We also achieved equal 
plasma glucose, insulin and FFA levels during the hyperinsulinemic euglycemic 
clamp (table 1). 
Hepatic glucose production 
Basal HGP was not different between the HF fed group and the control group (48±8 
µmol/kg.min versus 43±9 µmol/kg.min, 
ns). Under hyperinsulinemic conditions, 
HGP was significantly higher in the HF 
fed group versus the control group (30±9 
µmol/kg.min versus 16±10 µmol/kg.min, 
P<0.05). The relative inhibition of HGP 
was significantly less after HF feeding 
compared to the control group (35±20% 
versus 61±23%, P<0.05), indicating 
hepatic insulin resistance (figure 1).  
 
Whole body glucose uptake and muscle specific 2-DG uptake 
Basal whole body glucose uptake was not different between the HF fed group and 
the control group (48±8 µmol/kg.min versus 43±9 µmol/kg.min, ns). Under 
hyperinsulinemic conditions, whole body glucose uptake was not different between 
the HF fed group and the control group (66±10 µmol/kg.min versus 59±8 
µmol/kg.min, ns).  
Under hyperinsulinemic conditions, muscle-specific glucose uptake in the HF fed 
group was not significantly different from the control group (1.3±0.6 versus 1.3±0.3%/ 
g tissue). 
 
Table 1. Body weight and plasma glucose, insulin, and FFA concentrations of HF fed and control mice under  
basal and hyperinsulinemic conditions. 






 FFA  
(mmol/l) 
 






control 27±2 5.9 ± 0.7 8.7±1.2 0.8±0.5 4.1±1.0 1.0±0.2 0.5±0.2 
HF 27±2 6.7±1.2 8.8±0.7 1.9±1.4 3.7±1.7 1.0±0.2 0.6±0.2 



















Fig. 1. Inhibition of hepatic glucose production of
HF fed and control mice. Data are means ± SD for
n=9 in the control group and n=8 in the HF group.
*p < 0.05 vs control mice, as assessed by the




Tissue lipid levels 
Hepatic TG content of HF fed 
mice was 2.5-fold higher 
compared to the control group 
(32±10 versus 12±6 µg/mg 
protein, P<0.05), whereas muscle 
TG content was not significantly 
different between the two groups 
(27±9 versus 23±7 µg/mg protein, 
ns) (figure 2). 
 
mRNA expression levels 
Hypothalamic mRNA expression levels of NPY, AgRP, POMC, and CART were not 
different between HF fed and control mice (100±11% versus 111±20%; 100±20% 
versus 113±20%;100±47% versus 140±54%;100±33% versus 81±12%, respectively, 
ns). 
   
DISCUSSION 
 
This study shows that 2 weeks of high fat feeding in wildtype mice causes hepatic 
insulin resistance, reflected by decreased inhibition of hepatic glucose production, 
without affecting muscle specific insulin sensitivity. However, this was not associated 
with differences in hypothalamic mRNA expression of NPY, AgRP, POMC, and 
CART. Therefore, the hypothalamus does not seem to play a major role in the 
primacy of hepatic insulin resistance during a HF diet in mice.  
Although it was concluded from studies in the past in rats (17) and primates (4) 
that peripheral insulin resistance precedes the development of hepatic insulin 
resistance, our findings are in line with recent studies in rats (12) and dogs (11) 
documenting the primacy of hepatic insulin resistance during high fat feeding. 
Kraegen et al (12) used an extremely high fat diet (59% calorie fat) and found already 
after 3 weeks muscle specific insulin resistance as well. As this extreme diet is not 
relevant for the human situation we used a more human like high fat diet. However, 
even after 6 weeks, we did not observe muscle specific insulin resistance 
(unpublished data). 
In our study, 2 weeks of high fat feeding resulted in hepatic insulin resistance in 



















Fig. 2. TG-content determined in liver and skeletal
muscle of HF fed and control mice. Data are means ±
SD for n=7 in the control group and n=6 in the HF group.
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other groups [18;19] and could imply that hepatic steatosis is either a consequence 
of metabolic alterations elsewhere in the body and/or an active player in the 
pathophysiology of the metabolic syndrome.  
The mechanisms underlying the impairment of insulin action during a high fat diet 
are only partly known. Studies performed in vitro and in vivo showed an increase in 
gluconeogenesis (6,13) and a decrease in the suppressive effect of insulin on 
glycogenolysis (3). Shulman et al. postulated a more direct effect of FFA on hepatic 
glucose production, by interference of fatty acid derivatives with insulin signalling 
(10,20).  
The past years, data have become available on the potency of the hypothalamus 
to modulate insulin sensitivity during environmental fluctuations in nutrient availability. 
Independent of its stimulating effect on food intake and body weight, 
intracerebroventricular (icv) infusion of NPY causes hepatic insulin resistance in mice 
and rats (15,23). Conversely, subchronic (7 days) icv infusion of α-MSH enhances 
peripheral and hepatic insulin sensitivity in rats through stimulation of the 
melanocortin-3/4 receptor (16). These observations suggest that the balance 
between NPY/AgRP and POMC/CART neuronal activity is a determinant of 
peripheral and hepatic insulin sensitivity. In our study, however, we did not find 
significant changes in NPY, AgRP, POMC and CART mRNA expression levels in the 
whole hypothalamus during a 2 weeks HF diet, despite tissue-specific differences in 
insulin sensitivity. Since in our study, mRNA levels were measured in whole 
hypothalamus without regional dissection of the data, we cannot totally exclude 
involvement of certain specific hypothalamic areas in the regulation of hepatic insulin 
resistance during a high fat diet. To our knowledge, differential activation of NPY 
neurons in the medial and lateral part of the arcuate nucleus is possible (14,21), but 
no reports of opposite activation have been published. Therefore, a small effect could 
theoretically be masked by differential expression, but unlikely the absence of an 
effect, as we report in our study. The same holds true for POMC. In addition, the 
fasting condition might have a potential masking effect on neuropeptide expression, 
however, every feeding state could have a masking effect, depending on the 
neuropeptide of interest.  
Our observations are partly in line with those of other groups, who did not find an 
effect of a 2 weeks HF diet on NPY and AgRP mRNA expression levels in the 
hypothalamus of C57Bl/6 mice (25) and on NPY mRNA expression level in the 
hypothalamus of two strains of rats (Osborne-Mendel and S5B/Pl) (19) either. 
However, in contrast to our findings, Ziotopoulou et al. found a significant increase in 




hypothesized that the observed overexpression of POMC, a precursor of 
melanocyte-stimulating hormone, a potent inhibitor of food intake, is a response to 
overfeeding and positive energy balance to counteract the effect of high fat diet to 
promote increased food intake in an effort to maintain energy homeostasis. This is in 
line with findings of Bergen et al., who found compensatory hypothalamic changes in 
mRNA expression levels of NPY and POMC in A/J mice (resistant to diet-induced 
obesity) fed a high fat diet for 14 weeks (1). In line with our study, these studies imply 
that changes in hypothalamic mRNA expression levels of NPY, AgRP, POMC and 
CART are rather secondary or compensatory to high fat feeding, in order to maintain 
energy homeostasis, than primary, i.e. causing increased food intake during high fat 
feeding and thereby obesity and insulin resistance.  
From this study, we conclude that 2 weeks of high fat feeding in mice does not 
affect mRNA expression levels of NPY, AgRP, POMC or CART in the whole 
hypothalamus, despite induction of hepatic, but not peripheral, insulin resistance. 
Therefore, a major physiological role of these neuroendocrine factors in the induction 
of hepatic insulin resistance during a high fat diet seems less likely. 
 
This study was supported by the Netherlands organisation for Scientific Research (NWO) (grant 907-00-
002 to EPMC). This study is conducted in the framework of the ‘Leiden Center for Cardiovascular 
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Aims/hypothesis. The present study was conducted to evaluate the effects of central 
administration of melanotan II (MTII), a MC3/4 receptor agonist, on hepatic and whole-
body insulin sensitivity, independent of food intake and body weight. 
Methods. Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the 
left lateral ventricle in male C57Bl/6 mice. The animals had no access to food. The 
control group received three injections of distilled water. Whole-body and hepatic 
insulin sensitivity were measured by hyperinsulinaemic-euglycaemic clamp in 
combination with [3H]-glucose infusion. Glut4 mRNA expression was measured in 
skeletal muscle. 
Results. Plasma glucose and insulin concentrations under basal and 
hyperinsulinaemic conditions were similar in MTII- and placebo-treated mice. 
Endogenous glucose production (EGP) and glucose disposal in the basal state were 
significantly higher in MTII-treated mice than in the control group (71±22 vs. 43±12 
µmol/min/kg, p<0.01). During hyperinsulinaemia, glucose disposal was significantly 
higher in MTII-treated mice (151±20 vs. 108±20 µmol/min/kg, p<0.01). In contrast, the 
inhibitory effect of insulin on EGP was not affected by MTII (relative decrease of EGP: 
45±27 vs. 50±20%). Glut4 mRNA expression in skeletal muscle was significantly 
increased in MTII-treated mice (307±94 vs. 100±56%, p<0.01). 
Conclusions/interpretation. Intracerebroventricular administration of MTII acutely 
increases insulin-mediated glucose disposal, but does not affect capacity of insulin to 
suppress EGP in C57Bl/6 mice. These data indicate that central stimulation of 
melanocortin-3/4 receptors modulates insulin sensitivity in a tissue-specific manner, 










The hypothalamus integrates a multitude of behavioural and metabolic adaptations to food 
intake and starvation, necessary to maintain fuel homeostasis despite profound 
environmental variations in nutrient availability [1]. Two types of neuron in the arcuate 
nucleus of the hypothalamus are of major importance for the control of these processes: 
neurons co-expressing Agouti-related protein (AgRP) and neuropeptide Y (NPY), and 
neurons expressing pro-opiomelanocortin (POMC), the molecular precursor of alpha-
melanocyte-stimulating hormone (α-MSH) [2]. α-MSH binds to and stimulates melanocortin 
(MC) receptors. AgRP can bind to MC receptors as well, thereby inhibiting the POMC 
pathway [3]. NPY and POMC neuropeptides exert opposing effects on food intake and fuel 
homeostasis. NPY acts to promote anabolic pathways, whereas α-MSH counteracts the 
effects of NPY [4-6]. For instance, during food deprivation, NPY/AgRP neuronal activity is 
high while POMC/α-MSH expression levels are low [5], and this setting of the arcuate 
neuronal circuitry strongly stimulates food intake and reduces energy expenditure [7].  
Apart from its impact on food intake, intracerebroventricular (icv) administration of NPY 
acutely hampers capacity of insulin to inhibit hepatic glucose and VLDL production in 
C57Bl/6 mice, while insulin sensitivity of muscle and adipose tissue remains unaffected [8]. 
Conversely, chronic (7 days) icv infusion of α-MSH enhances peripheral and hepatic insulin 
sensitivity in rats through stimulation of the MC3/4 receptor [9] and POMC gene 
overexpression ameliorates insulin resistance in leptin-deficient mice independently of its 
effects on food intake and body weight [10]. In the latter studies, the effects on insulin 
sensitivity occur in the presence of a concomitant reduction in food intake and fat mass, 
which precludes distinction between putative direct effects of α-MSH or MC4 receptor on 
insulin sensitivity and indirect effects via feeding and body composition.  
In addition to its effect on of MC4 receptor activation on insulin sensitivity, decreased 
insulin concentration after central activation of the melanocortin neuronal circuitry, and 
increased levels of insulin in MC4 receptor knock-out mice even before the onset of 
detectable hyperphagia or obesity [11], have been documented. In humans, MC4 receptor 
mutations are associated with obesity [12;13].  
The aim of the present study was to document the direct effects of the activation of MC3/4 
receptors on insulin sensitivity (i.e. via mechanistic routes other than feeding and fat mass). 
As such, we injected (icv) melanotan II (MTII) [14], an agonist of the MC3/4 receptor [15], 
and quantified hepatic and peripheral insulin sensitivity of glucose metabolism during a 








Male 3-month-old C57Bl/6 mice (originating from The Jackson Laboratory [Bar Harbor, ME, 
USA] and bred in our own animal facility) were housed in a temperature- and humidity-
controlled room on a 12-h light-dark cycle with free access to standard mouse chow and 
water. All animal experiments were performed in accordance with the principles of laboratory 
animal care and regulations of Dutch law on animal welfare, and the protocol was approved 
by the institutional ethics committee for animal procedures.  
 
Surgical procedures.  
Mice were anaesthetised with 0.5 mg/kg medetomidine (Pfizer, Capelle a/d IJssel, The 
Netherlands), 5 mg/kg midazolam (Roche, Mijdrecht, The Netherlands), and 0.05 mg/kg 
fentanyl (Janssen-Cilag, Tilburg, The Netherlands). A 25-gauge guide cannula was 
stereotactically implanted into the left lateral ventricle using the following coordinates from 
Bregma: 0.46 mm posterior, 1.0 mm lateral and 2.2 mm ventral [16]. The guide cannula was 
secured to the skull surface using two screws and dental cement (AgnTho’s, Lidingö, 
Sweden). After a recovery period of 1 week, adequate placement of the cannulae was tested 
by measuring the feeding response to an acute icv injection of NPY (5 µg dissolved in 1 µl 
sterile water; Bachem, Bubendorf, Germany).  
 
Hyperinsulinaemic-euglycaemic clamp. 
Mice fasted for 24 h (with food withdrawn at 09.00 hours on the day before the experiment) 
were used. At 9.00 and 17.00 hours on the day before the experiment and at 8.45 hours on 
the day of the experiment mice were given 75 ng (in 1.5 µl distilled water) MTII 
(PhoenixEurope, Karlsruhe, Germany) or 1.5 µl distilled water (control group) icv. This dose 
of MTII was based on data from a tudy by Murphy et al [17], which showed inhibition of food 
intake using this dose. During icv injections, mice were lightly anaesthetised with isoflurane. 
All experiments were performed at 09.00 hours. Hyperinsulinaemic-euglycaemic clamps 
were performed as described previously [18;19]. During the experiments, mice were sedated 
with 6.25 mg/kg acepromazine (Sanofi sante animale, Libourne Cedex, France), 6.25 mg/kg 
midazolam (Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag). 
Basal rates of glucose turnover were measured by giving a primed (26 kBq) continuous 
(44 kBq/h) infusion of [3H]glucose (Amersham, Little Chalfont, UK) for 80 min. Subsequently, 
insulin was administered in a primed (4.1 mU) continuous (6.8 mU/h) i.v. infusion for 2 to 3 h 
to attain steady-state circulating insulin levels of about 4 ng/ml. The [3H]glucose infusion (44 
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kBq/h) was continued. A variable infusion of 12.5% D-glucose (in PBS) solution was also 
started and adjusted to maintain blood euglycaemia (measured at 10-min intervals via tail 
bleeding; Freestyle, TheraSense; Disetronic Medical Systems, Vianen, The Netherlands). 
Blood samples (60 µl) were taken during the basal period (after 60 and 80 min) and during 
the clamp period (when glucose levels in the blood were stable, and 20 and 40 min later) for 
measurement of plasma glucose, NEFAs, insulin and [3H]glucose specific activity.  
 
mRNA expression of Glut4.  
Real-time RT-PCR was used to measure mRNA expression levels of Glut4 (now known as 
Slc2a4) in skeletal muscle. Skeletal muscle was extracted from additional groups of mice 
directly at 10.30 hours following a 24-h fast and three icv injections with MTII or vehicle 
(injections at the same time points as in the hyperinsulinaemic-euglycaemic clamp 
experiment). Muscle was homogenised in 1.2 ml RNA-Bee (Tel-Test, Texas, USA) and total 
RNA was extracted according to the method described by Chomzcinsky and Sacchi [20]. The 
amount of RNA was determined by spectrophotometry (ND-1000 spectrophotometer; 
Nanodrop, Wilmington, DE, USA) at a wavelength of 260 nm. The quality was checked using 
the ratio of absorption at 260 nm : absorption at 280 nm. Complementary DNA (cDNA) was 
obtained out of total RNA. For RT-PCR, forward and reverse primers and TaqMan probe 
were designed from mouse-specific sequence data (Entrez, National Institutes of Health, 
Bethesda, MD, USA; and Ensembl, Wellcome Trust Sanger Institute, Cambridge, UK) using 
computer software (Primer Express, Applied Biosystems, Foster City, CA, USA). For each of 
the genes a Blast Search was done to reveal that sequence homology was obtained only for 
the target gene. Forward and reverse primers and TaqMan probe (5’ 
CCATGAGATCTGAGGCCACA 3’; 5’ GTATTTGCCGAAGTTGTAGCCG 3’; 5’ 
CAAGGGCAAGATCATCATGCACGACC 3’) of Glut4 were used. The TaqMan probe was 
labelled with 5’-6-carboxyfluorescein and 3’- (BHQ1). The genes encoding GAPDH (5’ VIC 
and 3’ BHQ1, Applied Biosystems) and cyclophilin (5’ TET and 3’ BHQ1, 5’ 
CAAATGCTGGACCAAACACAA 3’; 5’ GCCATCCAGCCATTCAGTCT 3’; 5’ 
CCGGTTCCCAGTTTTTTATCTGCACTGCC 3’) were used as housekeeping genes. PCR 
amplification was performed in a total reaction volume of 12.5 µl. The reaction mixture 
consisted of (1) qPCR MasterMix (Eurogentec, Seraing, Belgium); (2) the optimal primer and 
probe concentrations of Glut4 and the endogenous control; (3) nuclease-free water; and (4) 
cDNA. An identical cycle profile was used for all genes: 50°C for 2 min+95°C for 10 
min+[95°C for 15 s+60°C for 1 min]*40 cycles. Data were analysed using a comparative 
critical threshold (Ct) method where the amount of target normalised to the amount of 




is given by 2-∆∆Ct (Applied Biosystems). All samples were run together allowing relative 
comparisons of the samples. 
 
Analytical procedures.  
Plasma glucose and NEFA levels were determined using a commercially available kit 
(Instruchemie, Delfzijl, The Netherlands; Wako Pure Chemical Industries, Osaka, Japan). 
Plasma insulin and corticosterone concentrations were measured by ELISA (both ALPCO 
Diagnostics, Windham, NH, USA). For the measurement of plasma [3H]glucose, plasma was 
deproteinised with 20% trichloroacetic acid, dried to remove water and resuspended in 
distilled water. Samples were counted using scintillation fluid (Ultima Gold; Packard, 
Meridien, CT, USA). 
 
Calculations.  
Glucose turnover rate (µmol/min/kg) was calculated during the basal period and under 
steady-state clamp conditions as the rate of tracer infusion (dpm/min) divided by the plasma-
specific activity of [3H]glucose (dpm/µmol). The ratio was corrected for body weight. 
Endogenous glucose production (EGP) was calculated as the difference between the tracer-
derived rate of glucose appearance and the glucose infusion rate.   
 
Statistical analysis.  
Data are presented as mean±SD. Differences between groups were determined by Mann-
Whitney U-test for two independent samples. A p value of less than 0.05 was considered 
statistically significant. 
Table 1. Body weight, plasma corticosterone, NEFA, glucose and insulin concentration in vehicle (n=10) and 
MTII (n=8) mice 
  Basal   Hyperinsulinemic 
 Vehicle MTII Vehicle MTII 
Body weight (g) 17.9 ± 1.7 18.9 ± 1.6 -   -  
Corticosterone (mmol/l) 33.3 ± 17.5 37.8 ± 12.4 n.d. n.d. 
Glucose (mmol/l) 5.8 ± 1.0 6.7 ± 1.2 8.4 ± 1.0 8.2 ± 2.4 
NEFA (mmol/l) 0.55 ± 0.17 0.62 ± 0.17 0.26 ± 0.14 0.24 ± 0.08 
Insulin (ng/ml) 0.31 ± 0.11 0.31 ± 0.07 3.8 ± 2.9 3.7 ± 2.7 
Values are expressed as means ± SD. n.d. is not determined.
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Plasma parameters.  
Body weight, plasma corticosterone, glucose, NEFA and insulin concentrations under basal 
and hyperinsulinaemic conditions are shown in Table 1. In the basal state, these parameters 
did not differ between MTII- and vehicle-treated animals. Under steady-state 
hyperinsulinaemic conditions, plasma NEFA levels decreased approximately two-fold while 
insulin concentrations increased approximately ten-fold as expected. No differences were 
observed in plasma glucose, insulin and NEFA levels between MTII- and vehicle-treated 
mice during hyperinsulinaemia.  
 
Glucose turnover.  
Under basal conditions, EGP (and 
thereby glucose disposal) was 
significantly higher in MTII-treated 
animals than in vehicle-treated 
mice (71 ± 22 vs. 43 ± 10 
µmol/min/kg, p<0.01). During the 
hyperinsulinaemic period, the rate 
of glucose infusion necessary to 
maintain euglycaemia was 
significantly higher in MTII- treated 
animals than in vehicle-treated 
animals (114 ± 23 vs. 85 ± 20 
µmol/min/kg, p<0.05). Accordingly, 
the glucose disposal rate was 
significantly higher in MTII-treated 
animals (151 ± 20 vs. 108 ± 20 
µmol/min/kg, p<0.01, Fig. 1a). In 
contrast, hyperinsulinaemia 
suppressed EGP to a similar extent in MTII- treated mice and vehicle-treated mice (45 ± 27% 






























































Fig 1. a) insulin mediated glucose disposal in 24 hours fasted 
mice that received icv injections of MTII (n=10) (black bars) or 
vehicle (n=8) (white bars); b) inhibition of EGP by insulin in 24 
hours fasted mice that received icv injections of MTII (n=10) 
(black bars) or vehicle (n=8) (white bars). Values represent 







mRNA expression of Glut4.  
Glut4 mRNA expression in 
skeletal muscle was higher in 
the MTII-treated group 
compared to vehicle-treated 
mice (307 ± 94 vs. 100 ± 56 






This study shows that activation of MC3/4 receptors enhances whole-body sensitivity of 
glucose metabolism for insulin action in mice via mechanisms other than feeding and fat 
mass. In particular, MTII promotes insulin-mediated glucose disposal, but does not affect the 
capacity of insulin to suppress EGP. These observations are in line with the emerging notion 
that neural circuits control insulin action in peripheral tissues. 
Interestingly, Glut4 mRNA was increased in the muscle of MTII-treated animals, which 
suggests that activation of MC3/4 receptors enhances Glut4 gene expression to promote 
glucose uptake. The downstream mechanisms that actuate the effects of hypothalamic 
neuronal circuits on muscle Glut4 mRNA expression remain to be fully elucidated. The 
possibility that MTII increases locomotor activity and subsequently Glut4 mRNA expression 
in muscle cannot be ruled out. However, this seems unlikely since other studies have not 
observed any increase in locomotor activity following central administration of MTII [14;17]. 
Additional studies are required to elucidate the mechanisms involved in the modulation of 
insulin sensitivity by central administration of MTII. 
Glucose production in the basal state was higher in mice treated with MTII, but MTII did 
not affect the capacity of insulin to suppress EGP. Thus, central melanocortin pathways 
appear to directly impact endogenous glucose output. Although Fan et al. [11] reported 
decreased plasma insulin concentrations after icv administration of MTII, we did not find 
significant changes in basal plasma insulin concentrations as a potential explanation for the 
observed increase in basal glucose production. As Fan et al injected more than ten times the 
amount  we injected, this discrepancy may be explained by the difference in dose. Since 
MTII has been shown to activate the sympathetic nervous system [21;22] and sympathetic 
outflow promotes glucose production [23], it is conceivable that the autonomic nervous 




















Fig 2. GLUT4 mRNA expression levels in 24 hours fasted mice 
that received injections of MTII (n=6) (black bars) or vehicle (n=7) 
(white bars) in basal conditions. *p<0.01 versus vehicle. 
*
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metabolism. Unfortunately, our study does not provide data to evaluate this possibility. 
Alternatively, the brain could interact with the liver via the hypothalamo-pituitary-adrenal axis 
(HPA). Corticosteroids stimulate glucose production [24] and HPA activity is under strict 
control of the hypothalamus. In fact, corticotrophin-releasing hormone neurons in the 
paraventricular nucleus of the hypothalamus express MC4 receptors, and central MTII 
injection acutely enhances corticotrophin-releasing hormone and corticosterone release in 
rats [25]. However, MTII did not modify circulating corticosterone concentrations in our 
experimental setting, which refutes the hypothesis that central melanocortin pathways 
modulate the HPA axis to enhance glucose output. Interestingly, short-term fasting is 
accompanied by a decrease in EGP [26;27], and POMC/α-MSH mRNA expressions 
decreases concomitantly [5]. It is therefore tempting to speculate that blunted melanocortin 
signalling is involved in the decrease in EGP during fasting. If this was the case, 
administration of MTII may have prevented the normal decline in EGP associated with fasting 
in the present study.  
Although MTII increased basal EGP, it did not appear to affect capacity of insulin to 
suppress it. A previous paper [9] reports that chronic (7 days) icv infusion of α-MSH 
reinforces insulin action on glucose production (as well as on glucose disposal) in rats. 
However, this effect occurred in the presence of concomitant reductions in food intake, and 
body adiposity as well as these long-term sequelae of MTII administration can impact on 
insulin sensitivity. Our data indicate that activation of melanocortin circuits enhances insulin 
sensitivity independently of food intake and body weight, and that insulin action on glucose 
disposal is more sensitive to manipulation of MC3/4 receptors than it is capable of 
suppressing EGP.  
We recently showed that icv infusion of NPY in C57Bl/6 mice acutely hampers inhibitory 
effect of insulin on EGP but does not appear to affect insulin-mediated glucose disposal [8]. 
We have now shown that activation of melanocortin circuits reinforces insulin action on 
glucose disposal but does not affect suppression of glucose production. NPY and 
melanocortin circuits in the arcuate nucleus play critical roles in the control of fuel 
homeostasis in the face of fluctuations in nutrient availability. NPY neurons, active during 
fasting, stimulate feeding and inhibit energy expenditure, whereas melanocortin circuits, 
suppressed in fasting conditions, counteract NPY to exert opposing effects on energy 
balance. These behavioural and metabolic actions serve to protect the body against the 
perils of famine. Our data suggest that the brain also modulates glucose metabolism to 
further reinforce the line of defence. Enhanced activity of NPY neurons promotes glucose 
production, but reduced melanocortin activity hampers glucose disposal in fasting conditions, 
keeping glucose available as pivotal fuel for the brain. Conversely, diminished NPY-ergic and 




promote glucose disposal in response to food intake. The current findings may imply that 
MC-3/4 receptor agonists serve as "insulin sensitisers" in the treatment of the metabolic 
syndrome and type 2 diabetes mellitus. However, tachyphylaxis to chronic MTII 
administration has been observed in mice and rats [28;29]. In addition, the present study 
shows that MTII increases basal EGP. Thus, the impact of chronic MTII administration on 
glucose metabolism in (insulin resistant) animal models and humans remains to be 
established. 
In conclusion, the present study shows that activation of central melanocortin-3/4 
receptors by melanotan II enhances insulin sensitivity of whole body glucose disposal, 
independently of food intake and fat mass, but does not affect  ability of insulin to suppress 
EGP. These observations are in line with the emerging notion that neural circuits, apart from 
their effects on feeding, modulate insulin sensitivity to adapt metabolic conditions in the face 
of environmental fluctuations in nutrient availability. 
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Peptides YY3-36 (PYY3-36) is released by the gut in response to nutrient 
ingestion. It modulates the activities of orexigenic neuropeptide Y (NPY) 
neurons and anorexigenic proopiomelanocortin (POMC) neurons in the 
hypothalamus to inhibit food intake. Because both NPY and POMC have also 
been shown to impact insulin action, we wondered whether PYY3-36 could 
improve insulin sensitivity. To address this question, we examined the acute 
effect of intravenous PYY3-36 on glucose and free fatty acid (FFA) flux during a 
hyperinsulinemic-euglycemic clamp in mice maintained on a high-fat diet for 2 
weeks before the experiment. We also evaluated the effects of PYY3-36 infusion 
on glucose uptake in muscle and adipose tissue in this experimental context. 
Under basal conditions, none of the metabolic parameters were affected by 
PYY3-36. Under hyperinsulinemic conditions, glucose disposal was significantly 
increased in PYY3-36-infused compared with vehicle-infused mice (103.8 ± 10.9 
vs. 76.1 ± 11.4 µmol/min/kg, respectively; P=0.001). Accordingly, glucose 
uptake in muscle and adipose tissue was greater in PYY3-36-treated animals, 
although the difference with controls did not reach statistical significance in 
adipose tissue (muscle: 2.1 ± 0.5 vs. 1.5 ± 0.5 µmol/ g tissue, P=0.049; adipose 
tissue: 0.8 ± 0.4 vs. 0.4 ± 0.3 µmol/ g tissue; P=0.08). In contrast, PYY3-36 did not 
impact insulin action on endogenous glucose production or FFA metabolism. 
These data indicate that PYY3-36 reinforces insulin action on glucose disposal 
in mice fed a high-fat diet, through a mechanism that is independent of food 
intake and body weight. In contrast, it leaves glucose production and lipid flux 








Peptide YY (PYY) belongs to a family of peptides that is critically involved in the 
regulation of appetite. It is synthesized in specialized cells (L-cells) that are found 
primarily in the distal gastrointestinal tract. Circulating PYY levels rise within 15 
minutes after a meal in proportion to the amount of calories ingested and remain 
elevated for ~6 h (1). The two natural forms of this peptide, PYY1-36 and PYY3-36, have 
opposing effects on food intake (2): PYY1-36 stimulates appetite whereas PYY3-36 (the 
major circulating form) inhibits feeding (3-5).   
PYY3-36 reduces food intake by acting on appetite regulation centers in the 
hypothalamus (3;6). Specifically, PYY3-36 is an agonist of the presynaptic 
neuropeptide Y (NPY) Y2 receptor, which inhibits NPY neuronal activity in the 
arcuate nucleus and thereby activates adjacent proopiomelanocortin (POMC) 
neurons (3). In addition to their critical role in the control of feeding, both NPY and 
POMC affect insulin action. Intracerebroventricular infusion of NPY induces 
hyperinsulinemia and insulin resistance in rats (7;8). In contrast, central 
administration of α-melanocyte stimulating hormone, a splice-product of the POMC 
peptide, enhances insulin sensitivity (9). In view of the fact that PYY3-36 inhibits NPY 
neuronal activity and activates that of POMC, we wondered whether it could improve 
insulin sensitivity “directly” (i.e., through a mechanism independent of food intake and 
body weight). To address this question, we infused PYY3-36 intravenously and 
quantified its acute effects on glucose and fatty acid flux during a hyperinsulinemic-
euglycemic clamp in mice without access to food during the experiment. 
 
MATERIALS AND METHODS 
 
Animals 
Male C57BL/6J mice were housed in a temperature-controlled room on a 12-h 
light/dark cycle and were fed a high-fat diet (43 energy% fat derived from bovine lard) 
with free access to water for 2 weeks to induce insulin resistance. All animal 
experiments were performed in accordance with the regulations of Dutch law on 
animal welfare, and the institutional ethics committee for animal procedures 
approved the protocol. 
 




A total of 36 mice were fasted overnight with food withdrawn at 5:00 P.M. the day 
before the study. The next day, hyperinsulinemic-euglycemic clamps were performed 
as described earlier (10). PYY or vehicle was administered as a primed (0.15 µg)-
continuous (0.25 µg/h) intravenous infusion during the whole experiment (basal and 
hyperinsulinemic period). In one series of experiments, glucose turnover was 
quantified, and in another series, free fatty acid (FFA) turnover was determined. First, 
basal rates of glucose or FFA turnover were measured by giving a primed-continuous 
infusion of 3H-glucose (prime: 0.7 µCi; continuous: 1.2 µCi/h; Amersham, Little 
Chalfont, U.K.) or 14C-palmitate (prime: 1.8 µCi; continuous: 3 µCi/h; Amersham), 
respectively, for 80 min. Subsequently, insulin was administered in a primed (4.1 
mU)-continuous (6.8 mU/h) intravenous infusion for 2-3 h to attain steady-state 
circulating insulin levels of ~6 ng/ml. A variable infusion of 12.5% D-glucose was 
used to maintain euglycemia, measured at 10 min intervals via tail bleeding 
(Freestyle; TheraSense, Disetronic Medical Systems, Vianen, The Netherlands). 
Blood samples (75 µl) were taken during the basal period (after 60 and 80 min) and 
during the clamp period (when glucose levels were stable and 20 and 40 min later) 
for determination of plasma glucose, FFA, and insulin concentrations and [3H]glucose 
and [14C]palmitate specific activities.  
To assess insulin-mediated glucose uptake in individual tissues, 2-deoxy-D-[3H] 
glucose (2-DG; Amersham) was administered as a bolus (1µCi) 40 minutes before 
the end of the clamp experiments in which FFA turnover was measured. At the end 
of the clamp, mice were killed, and muscle and adipose tissue were isolated and 
frozen in liquid nitrogen for subsequent analysis. 
 
Analytical procedures  
Plasma levels of glucose and FFAs were determined using commercially available 
kits (Instruchemie, Delfzijl, The Netherlands, and Wako, Neuss, Germany). Plasma 
insulin and PYY3-36 concentrations were measured by a mouse insulin enzyme-linked 
immunoabsorbant assay and PYY3-36 radioimmunoassay (Alpco, Windham, NH, and 
Phoenix Pharmaceuticals, Belmont, CA). Total plasma 3H-glucose was determined in 
7.5 µl plasma and in supernatants after trichloroacetic acid (20%) precipitation and 
water evaporation to eliminate tritiated water. Total plasma 14C-palmitate was 
determined in 7.5 µl plasma after extraction of lipids by a modification of Bligh and 
Dyer’s (11) method. Briefly, 7.5 µl plasma was dried and resolved in 100 µl water. 
Then 1.1 ml demi-water and 4.5 ml methanol:chloroform (2:1) were added and mixed 
thoroughly, after which 1.5 ml chloroform was added and mixed, and, finally, 1.5 ml 
demi-water was added and mixed. After centrifugation, the chloroform layer was 
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collected, and the FFA fraction was separated from other lipid components by thin-
layer chromatography (TLC) on silica gel plates.  
 
Tissue analysis  
For determination of tissue 2-DG uptake, the homogenate of muscle and adipose 
tissue was boiled, and the supernatant was subjected to an ion-exchange column to 
separate 2-DG-6-phosphate from 2-DG as described previously (10;12;13). 
 
Calculations  
Turnover rates of glucose and FFAs (µmol/min/kg) were calculated during the basal 
period and in steady-state clamp conditions as the rate of tracer infusion (dpm/min) 
divided by the plasma specific activity of 3H-glucose or 14C-palmitate (dpm/µmol). The 
ratio was corrected for body weight. Endogenous glucose production (EGP) was 
calculated as the difference between the tracer-derived rate of glucose appearance 
and the glucose infusion rate. 
Tissue-specific glucose uptake in muscle and adipose tissue was calculated from 
tissue 2-DG content, corrected for plasma specific activity and expressed as 
micromoles per gram of tissue.   
 
Statistical analysis  
Differences between groups were determined by Mann-Whitney’s non-parametric 
test for two independent samples. P < 0.05 was considered statistically significant. All 




Mice were 16-18 weeks old during the experiments. Body weight was 23.3 ± 1.2 g in 
the control group and 22.8 ± 1.4 g in the PYY group. 
 
Plasma parameters  
Plasma glucose, FFA, insulin, and PYY3-36 concentrations in basal and 
hyperinsulinemic conditions are shown in table 1. In the basal state, plasma 
parameters did not differ between PYY- and vehicle-infused animals, except for the 
plasma PYY3-36 concentration. Under steady-state clamp conditions, plasma insulin 
and glucose concentrations were similar in both groups. Hyperinsulinemia 





Glucose turnover  
Under basal conditions, glucose disposal was similar in PYY- and vehicle-infused 
mice (39,5 ± 10.9 vs. 45.9 ± 12.6 µmol/min/kg, respectively; P=0.19) (Figure 1a). The 
rate of glucose infusion necessary to maintain euglycemia during insulin infusion was 
significantly higher in PYY-infused mice than in vehicle-infused animals (89.1 ± 7.1 
vs. 50.9 ± 13.6 µmol/min/kg, P=0.001), indicating that intravenous PYY3-36 
administration acutely enhances insulin sensitivity. Hyperinsulinemia increased 
glucose disposal in both groups. However, the disposal rate was significantly higher 
in PYY-infused animals compared with vehicle-infused controls (103.8 ± 10.9 vs. 
76.1 ± 11.4 µmol/min/kg, respectively; P=0.001) (Figure 1a). In contrast, EGP, which 
was similar in PYY- and vehicle-treated mice under basal conditions, was 
Table 1. Plasma parameters in overnight fasted mice that received an i.v.-infusion of PYY or vehicle 
under basal or hyperinsulinemic conditions. Values represent mean ± SD for at least 7 mice per group. 
  Basal  Hyperinsulinemic 
 Vehicle PYY Vehicle PYY 
Glucose (mmol/l) 4.9 ± 0.6 5.0 ± 0.6 9.0 ± 0.9 9.2 ± 2.0 
FFA (mmol/l) 0.9 ± 0.2 1.0 ± 0.2 0.4 ± 0.1 0.5 ± 0.1 
Insulin (ng/ml) 0.3 ± 0.1 0.3 ± 0.1 5.2 ± 2.9 6.7 ± 2.7 
PYY3-36 (pg/µl) < 1 3.8 ± 0.7 < 1 3.2 ± 0.7 










































Fig. 1. Glucose disposal (a) and endogenous glucose production (b) in overnight-fasted mice before
(basal) and during (hyperinsulinemic) a hyperinsulinemic-euglycemic clamp. Before and during insulin
infusion the animals received an intravenous infusion of PYY or vehicle. Values represent mean ± SD for
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suppressed by insulin to the same extent in both groups (by 62 ± 29 vs. 42 ± 18% 
from basal, respectively; P=0.30) (Figure 1b).  
 
Tissue-specific glucose uptake  
Insulin-mediated 2-DG uptake in muscle and adipose tissue was greater in PYY-
treated animals, but the difference with controls did not reach statistical significance 
in adipose tissue (muscle: 2.1 ± 0.5 vs. 1.5 ± 0.5 µmol/g tissue, P=0.049; adipose 
tissue: 0.8 ± 0.4 vs. 0.4 ± 0.3 µmol/g tissue; P=0.08) (Figure 2)  
 
FFA turnover  
Basal FFA turnover  (38.0 ± 14.2 vs. 42.3 ± 9.9 µmol/min/kg) was not different 
between PYY- and vehicle-infused animals and was suppressed to a similar extent 
by insulin in both groups (22.4 ± 12.3 vs. 
21.3 ± 10.9 µmol/min/kg in PYY- and 



















































 Fig. 2. Muscle-specific (a) and adipose tissue-specific (b) glucose uptake under hyperinsulinemic 
conditions in overnight-fasted mice that received an intravenous infusion of PYY or vehicle. Values 





















Fig. 3. Free fatty acids (FFA) turnover in 
overnight fasted mice before (basal) and 
during (hyperinsulinemic) a hyperinsulinemic-
euglycemic clamp. Before and during insulin 
infusion the animals received an intravenous 
infusion of PYY or vehicle. Values represent 






Here we show that intravenous PYY3-36 administration acutely reinforces insulin 
action on glucose disposal in overnight-fasted mice maintained on a high-fat diet. In 
contrast, PYY3-36 does not appear to impact the effect of insulin on EGP or FFA 
metabolism in this experimental context.  
PYY3-36 clearly enhanced insulin-induced glucose disposal as determined by tracer 
dilution methodology. Accordingly, 2-DG uptake in muscle and adipose tissue under 
hyperinsulinemic conditions was higher during PYY3-36 infusion, albeit the difference 
with control attained statistical significance only for muscle. In contrast, PYY3-36 did 
not significantly impact the capacity of insulin to inhibit EGP. Insulin action on FFA 
metabolism was not affected by PYY3-36, either, as indicated by similar fatty acid 
turnover rates during hyperinsulinemia in PYY3-36- and saline-infused animals. In light 
of the current experimental context, these data suggest that PYY3-36 reinforces the 
impact of insulin on glucose disposal through a mechanism that is independent of 
food intake and body weight. In contrast, it appears to leave insulin action on glucose 
production and FFA turnover largely unaffected. 
The plasma PYY3-36 concentration rose to 3.2 ± 0.7 pg/µl in response to PYY 
infusion. Relatively few studies have looked at the physiology of circulating PYY3-36 in 
rodents. According to a recent paper by Batterham et al.(3), postprandial PYY3-36 
concentrations amount to 112 pmol/l (~0.4 pg/µl) in freely feeding rats. In a study by 
Lee et al (14), plasma PYY levels in fasting mice were 0.18 pg/µl, which accords with 
our data (table 1). We are not aware of any study measuring postprandial PYY3-36 
concentrations in mice. Thus, the dose of PYY3-36 we administered may have induced 
supraphysiological PYY3-36 levels. Therefore, our data do not allow a definitive 
inference as to whether the postprandial rise of circulating PYY3-36  can reinforce 
insulin action.  
Postprandial PYY3-36 release is decreased in obese compared with lean subjects, 
and circulating levels correlate negatively with BMI. Conversely, intravenous PYY3-36 
infusion significantly reduces food intake in humans (15), and repeated 
administration of PYY3-36 attenuates weight gain in rodents (3). These findings 
suggest that diminished PYY3-36 release may contribute to the pathogenesis of 
obesity in animals and humans. The observations presented here allow us to 
hypothesize that low circulating PYY3-36 levels may also compromise insulin action in 
obese subjects. Moreover, perhaps even more important, the data suggest that 
PYY3-36 or synthetic analogs of this peptide may be useful tools in the clinical 
management of obesity and insulin resistance. 
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It remains to be established whether PYY3-36 acts through hypothalamic neural 
circuits (by analogy with the mechanism guiding its effects on appetite) to enhance 
insulin-mediated glucose disposal. Because PYY3-36 is a high-affinity agonist to the 
Y2 receptor (2) and the distribution of this receptor subtype is largely confined to the 
central nervous system (particularly the arcuate nucleus of the hypothalamus) (16), it 
is most likely that PYY3-36 modulates insulin action by activation of Y2 receptors in the 
brain. As alluded to earlier, Y2 receptor signaling inhibits NPY neuronal activity in the 
arcuate nucleus of the hypothalamus and thereby activates adjacent POMC neurons 
(3). Hypothalamic overexpression of NPY induces obesity and insulin resistance in 
mice (7;8), whereas activation of melanocortin receptor subtypes 3 and 4 in the brain 
enhances insulin sensitivity (9). Thus, the present data are in keeping with the 
contention that PYY3-36 modulates insulin action via hypothalamic Y2 receptor. The 
downstream mechanisms that actuate the effects of hypothalamic neuronal circuits 
on muscle and adipose tissue remain to be fully elucidated. At this point, vagotomy 
was shown to prevent the hyperinsulinemic effects of NPY, which suggests that the 
autonomic nervous system may be involved (17). Also, adrenalectomy prevents the 
obesity syndrome produced by chronic central NPY infusion and reverses the obese 
phenotype in leptin-deficient ob/ob mice (18;19), indicating that the pituitary-adrenal 
ensemble may also serve as a second messenger. Thus, neural and/or endocrine 
mechanistic routes may convey signals from hypothalamic nuclei to peripheral 
tissues to orchestrate energy balance and fuel flux. It is conceivable that similar 
routes partake in the control of insulin action by PYY3-36. 
In conclusion, PYY3-36 reinforces insulin action in mice maintained on a high-fat 
diet through a mechanism that is independent of food intake and body weight. In this 
context, PYY3-36 appears to predominantly impact insulin-mediated glucose disposal, 
whereas it leaves insulin action on glucose production largely unaffected. These 
novel data suggest that PYY3-36 or synthetic analogues of this peptide may be 
valuable assets to our armamentarium of drugs designed to battle insulin resistance 
and type 2 diabetes mellitus. 
 
The research described in this paper is supported by the Dutch Scientific Research Council / 
Netherlands Heart foundation (projects 980-10-017 and 907-00-002). This study is conducted in the 
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Aims/hypothesis. PYY3-36 is a gut-derived hormone, that acts on hypothalamic nuclei 
to modulate energy metabolism. We recently showed, that PYY3-36 acutely reinforces 
insulin action on glucose disposal in insulin resistant mice. However the long-term 
effects of PYY3-36 on insulin sensitivity are still unknown.  
Methods. To adress this question, we examined the effects of chronic PYY3-36 
administration (2.5 µg/day s.c. for 7 days) on glucose turnover during a 
hyperinsulinemic-euglycemic clamp in C57BL6 mice maintained on a high fat diet for 
16 weeks before the experiment. In addition, metabolic efficacy of continuous vs. 
intermittent administration of PYY3-36 was evaluated.  
Results. Under hyperinsulinemic conditions, glucose disposal was significantly 
increased in PYY3-36 treated mice vs. vehicle-treated mice (78.8 ± 13.3 vs. 63.4 ± 15.5 
µmol/min/kg, respectively, P=0.012). Tissue specific glucose uptake was significantly 
increased in adipose tissue (0.5 ± 0.2 vs. 0.2 ± 0.1 µmol/ g tissue; P=0.006), but not in 
muscle (2.2 ± 1.4 vs. 1.6 ± 0.8 µmol/ g tissue for PYY3-36 and vehicle-treated animals, 
respectively, P=0.38) of PYY3-36 treated animals. In contrast, insulin action on 
endogenous glucose production was not significantly affected. Furthermore, none of 
these metabolic parameters were affected by the mode of PYY3-36 administration 
(continuous or intermittent). 
 Conclusions/interpretation. Chronic PYY3-36 administration enhances the ability of 
insulin to promote glucose disposal, whereas it does not significantly affect 
endogenous glucose production in C57BL6 mice maintained on a high fat diet for 16 
weeks. In addition, this study shows that continuous and intermittent administration 
are equally effective in this respect.  
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INTRODUCTION 
The metabolic syndrome comprises a cluster of anomalies that increase the risk of 
cardiovascular disease and type 2 diabetes mellitus: hyperglycemia, abdominal obesity, 
hypertriglyceridemia, hypertension and low levels of high-density lipoprotein (HDL) 
cholesterol [1-3]. Insulin resistance may underlie the majority of these pathologies [4] and 
therapies that effectively reinforce insulin action may therefore ameliorate the risk profile of 
metabolic syndrome patients [5;6]. 
Diet-induced obese, insulin resistant C57BL6-mice have increased levels of neuropeptide 
Y (NPY) and decreased levels of pro-opiomelanocortin (POMC) in hypothalamic nuclei [7-9]. 
These features of hypothalamic neural circuits may be involved in the pathogenesis of the 
metabolic syndrome, as intracerebroventricular (icv) administration of NPY or antagonists of 
POMC induce insulin resistance [10-13]. Therefore, antagonists of NPY and/or agonists of 
POMC signalling may be useful tools in the clinical management of this syndrome. Peptide 
YY3-36 (PYY3-36) is released in response to food intake by L-cells in the distal gastrointestinal 
tract. It acts via Y2 receptors on NPY neurons in the arcuate nucleus to inhibit NPY neuronal 
activity and thereby activates adjacent POMC neurons [14;15]. We recently found that PYY3-
36 administration acutely reinforces insulin action on glucose disposal through a mechanism 
that is independent of food intake and body weight [16]. This finding suggests that PYY3-36 
may be used as a therapeutic tool in the clinical management of insulin resistance and the 
metabolic syndrome. However, the metabolic effects of long-term PYY3-36 administration are 
currently unknown, and waning of early impact may occur during chronic treatment through 
down regulation of receptor expression or function [17;18]. Therefore, the aim of this study 
was to investigate the long-term effects of PYY3-36 on insulin action by administering PYY3-36 
subcutaneously for 7 days in mice fed a high-fat diet, and quantifying the effects on glucose 
production and disposal during a hyperinsulinemic euglycemic clamp study. As the 
physiology of PYY3-36 entails intermittent release in response to food intake, we also 
examined whether continuous and intermittent administration of PYY3-36 impact glucose 
metabolism differentially in this experimental context.  
 
MATERIAL AND METHODS 
 
Animals  
Male C57BL6 mice were housed in a temperature-controlled room on a 12-hour light-dark 
cycle and were fed a high fat diet (43 energy% fat derived from bovine lard) with free access 
to water for 16 weeks to induce insulin resistance. After 15 weeks of high fat diet, osmotic 
minipumps (Alzet minipump, model 2001, Charles River, Maastricht, The Netherlands) were 




a saline (n = 15) or PYY3-36 (2.5 µg/day, n = 5) infusion via the osmotic minipump at a rate of 
0.5 µl/h for 7 days. In addition, daily subcutaneous injections (50 µl at 09.00 am) of saline or 
PYY3-36 (2.5 µg) were given, where mice receiving continuous PYY3-36 treatment were 
additionally injected with saline, and mice receiving saline by minipump were assigned to 
receive either saline (n = 8) or PYY3-36 (n = 7) by injection. Thus, glucose kinetics were 
determined in 2 experimental groups: 1) receiving saline and 2) receiving PYY3-36, where 
PYY3-36 was administered continuously by minipump or intermittently by daily subcutaneous 
injection.  All animal experiments were performed in accordance with the regulations of 
Dutch law on animal welfare and the institutional ethics committee for animal procedures 
approved the protocol. 
 
Hyperinsulinemic euglycemic clamp 
Mice were fasted overnight with food withdrawn at 05.00 pm the day prior to the study. The 
next day, hyperinsulinemic euglycemic clamps were performed as described earlier [19]. 
First, basal rates of glucose turnover were measured by giving a primed (0.7 µCi) continuous 
(1.2 µCi/h) infusion of 14C-glucose (Amersham, Little Chalfont, U.K.) for 80 min. 
Subsequently, insulin was administered in a primed (4.1 mU) continuous (6.8 mU/h) i.v. 
infusion for 2 to 3 hours to attain steady state circulating insulin levels of ~3.5 ng/ml. A 
variable infusion of 12.5% D-glucose was used to maintain euglycemia (measured at 10 min 
intervals via tail bleeding, Freestyle, TheraSense, Disetronic Medical Systems BV, Vianen, 
The Netherlands). Blood samples (75 µl) were taken during the basal period (after 60 and 80 
minutes) and during the clamp period (when glucose levels were stable and 20 and 40 
minutes later) for determination of plasma glucose, non-esterified fatty acids (NEFA), insulin 
and PYY3-36 concentrations and 14C-glucose specific activities.  
To assess insulin-mediated glucose uptake in individual tissues, 2-deoxy-D-[3H] glucose 
(2-[3H]DG; Amersham, Little Chalfont, UK) was administered as a bolus (1µCi), 40 minutes 
before the end of the clamp experiments. At the end of the clamp, mice were sacrificed and 
muscle and adipose tissue were isolated and frozen in liquid nitrogen for subsequent 
analysis. 
 
Analytical procedures  
Plasma levels of glucose and NEFA were determined using commercially available kits 
(Instruchemie, Delfzijl, The Netherlands and Wako, Neuss, Germany). Plasma insulin and 
PYY3-36 concentrations were measured by a mouse insulin ELISA and PYY3-36 RIA 
(Mercodia, Uppsala, Sweden; Phoenix pharmaceuticals, Belmont, CA, USA; sensitivity of 1 
pg/µl for the PYY3-36 RIA). Total plasma 14C-glucose was determined in 7.5 µl plasma and in 
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supernatants after trichloroacetic acid (20%) precipitation and water evaporation to eliminate 
tritiated water.  
 
Tissue analysis  
For determination of tissue 2-DG uptake, the homogenate of muscle and adipose tissue was 
boiled and the supernatant was subjected to an ion-exchange column to separate 2-DG-6-P 
from 2-DG as described previously [19-21]. 
 
Calculations  
Turnover rates of glucose (µmol/min/kg) were calculated during the basal period and in 
steady-state clamp conditions as the rate of tracer infusion (dpm/min) divided by the plasma 
specific activity of 14C-glucose (dpm/µmol). The ratio was corrected for body weight. EGP 
was calculated as the difference between the tracer-derived rate of glucose appearance and 
the glucose infusion rate. 
Tissue-specific glucose uptake in muscle and adiopose tissue was calculated from tissue 
2-DG content, corrected for plasma specific activity and expressed as µmol per gram of 
tissue.   
 
Statistical analysis  
Differences between groups were determined by Mann-Whitney non-parametric test for 2 
independent samples. A P-value < 0.05 was considered statistically significant. All values 




Body weight did not differ between PYY3-36 and vehicle-infused animals (after 7 days of 
PYY3-36/saline administration: 28.0 ± 3.7 gram in the PYY3-36 group and 28.3 ± 1.5 gram in 
the control group, P=0.68). Overnight food intake was measured at day 2 and day 5 of PYY3-
36/saline administration and was similar in both groups (day 2: 2.37 ± 0.68 vs. 2.32 ± 0.33 
gram, P=0.96; day 5: 2.76 ± 0.54 vs. 2.75 ± 0.43 gram, P=0.97 in PYY3-36 and vehicle-treated 
animals, respectively). Furthermore, body weight and overnight food intake was not different 
in groups receiving continuous or intermittent PYY3-36 treatment (body weight: 29.5 ± 3.9 vs. 
26.9 ± 3.4 gram, P=0.20; food intake day 2: 2.14 ± 0.98 vs. 2.48 ± 0.56 gram, P=0.38; day 5: 








  Basal  Hyperinsulinemic  
 Vehicle PYY3-36 Vehicle PYY3-36 
Glucose (mmol/l) 7.7 ± 1.3 8.4 ± 1.5 8.4 ± 1.2 9.4 ± 0.8 
NEFA (mmol/l) 1.1 ± 0.2 0.9 ± 0.2 0.6 ± 0.1 0.5 ± 0.1 
Insulin (ng/ml) 0.7 ± 0.3 0.7 ± 0.4 3.2 ± 0.9 3.6 ± 0.8 
 
 
Plasma parameters  
Plasma glucose, NEFA, and insulin concentrations in basal and hyperinsulinemic conditions 
are shown in table 1. Plasma glucose and insulin concentrations did not differ between 
vehicle and PYY3-36 treated animals under basal and steady state clamp conditions. 
Furthermore, continuous and intermittent PYY3-36 
administration had similar impact on these 
parameters, except for the plasma glucose levels 
under basal conditions, which were slightly but 
significantly higher in the group that received 
continuous PYY3-36 administration (basal glucose: 
9.3 ± 0.9 vs. 7.7 ± 1.5 mmol/l, P=0.048; 
hyperinsulinemic glucose: 9.9 ± 0.8 vs. 9.1 ± 0.6 
mmol/l, P=0.073; basal insulin: 0.9 ± 0.4 vs. 0.5 ± 
0.3 ng/ml, P=0.073; hyperinsulinemic insulin: 3.9 ± 
1.0 vs. 3.4 ± 0.6 ng/ml, P=0.43). Plasma NEFA 
concentrations were slightly, but significantly, 
lower in PYY3-36 treated mice in basal (P=0.025) 
and steady state clamp (P=0.031) conditions, 
where continuous and intermittent PYY3-36 
administration did not have differential effects 
(basal NEFA: 0.9 ± 0.3 vs. 0.9 ± 0.1 mmol/l, 
respectively, P=0.76; hyperinsulinemic NEFA: 0.5 
± 0.1 vs. 0.4 ± 0.1 mmol/l, respectively, P=0.073). 
Plasma PYY3-36 concentrations in basal and 






















































Fig 1. Insulin mediated glucose disposal
(a) and inhibition of endogenous glucose
production (EGP) by insulin (b) in overnight
fasted mice before (basal) and during
(hyperinsulinemic) a hyperinsulinemic
euglycemic clamp study. Prior to the clamp
experiment the animals received PYY3-36
(n=12) or vehicle (n=8) for 7 days. Values
represent the means ± SD. *P<0.05 vs.
vehicle.
Table 1. Plasma parameters under basal or hyperinsulinemic conditions in overnight fasted mice 
that received PYY3-36 (n=12) or vehicle (n=8)  for 7 days. 
Data are the means ± SD. * <0.05 vs. vehicle 
89
Chronic PYY3-36 treatment and insulin action 
 89
detection level in all groups (<1 pg/µl), except for the basal condition of the mice that 
received intermittent PYY3-36 administration (3.7 ± 0.8 pg/µl). 
 
Glucose turnover  
In basal conditions, glucose disposal was similar in 
PYY3-36 and vehicle-treated mice (52.0 ± 10.5 vs. 50.4 
± 10.4 µmol/min/kg, respectively, P=0.68). The rate of 
glucose infusion necessary to maintain euglycemia 
during insulin infusion was significantly higher in 
PYY3-36 treated mice than in vehicle-treated animals 
(54.0 ± 11.4 vs. 33.4 ± 11.6 µmol/min/kg, P=0.000), 
indicating that chronic PYY3-36 administration 
enhances whole body insulin sensitivity. Continuous 
and intermittent administration of PYY3-36 had similar 
effects on the glucose infusion rate (54.7 ± 9.2 vs. 
53.6 ± 10.2 µmol/min/kg, respectively, P=0.27). 
Hyperinsulinemia increased glucose disposal in both 
groups. However, the disposal rate was significantly 
higher in PYY3-36 treated animals compared with 
vehicle-treated controls (78.8 ± 13.3 vs. 63.4 ± 15.5 
µmol/min/kg, respectively, P=0.012, Figure 1a) and 
was similar in animals treated by continuous and 
intermittent administration (81.2 ± 13.8 vs. 77.1 ± 13.7 
µmol/min/kg, respectively, P=0.64). Endogenous 
glucose production was similar in PYY3-36 and vehicle-
treated mice in basal conditions and was suppressed 
by insulin to the same extent in both groups (by 54 ± 18 vs. 40 ± 26% from basal in PYY3-36 
vs. vehicle treated groups, respectively; P=0.27, Figure 1b), where percent inhibition did not 
differ between animals receiving continuous or intermittent PYY3-36 treatment. (52 ± 25 vs. 55 
± 12% from basal, respectively, P=0.53).  
 
Tissue-specific glucose uptake  
Insulin-mediated 2-deoxy-glucose uptake was measured in muscle and adipose tissue. In 
muscle, 2-deoxy-glucose was similar in both groups (2.2 ± 1.4 vs. 1.6 ± 0.8 µmol/ g tissue for 
PYY3-36 and vehicle-treated animals, respectively, P=0.38). In adipose tissue 2-deoxy-
glucose uptake was significantly increased in PYY3-36 treated animals compared with vehicle 
















































 Fig 2. Muscle-specific (a) and adipose tissue-specific (b) glucose uptake under 
hyperinsulinemic conditions in overnight 
fasted mice that received PYY3-36 (n=11) or 
vehicle (n=7) for 7 days. Values represent 







Here we show that chronic PYY3-36 administration improves whole body insulin sensitivity of 
glucose metabolism in C57BL6 mice maintained on a high fat diet for 16 weeks. In particular, 
PYY3-36 treatment enhances the ability of insulin to promote glucose disposal via mechanistic 
routes that are independent of food intake or body weight. In addition, this study documents 
that continuous and intermittent administration of PYY3-36 reinforce insulin action to a similar 
extent. 
These data corroborate our previous findings, which unveil similar acute effects of  PYY3-
36 administration on insulin action [16], and support the emerging concept of neural circuits 
controlling fuel flux, independent of their impact on food intake and body weight. In addition, 
our data indicate that the effects of PYY3-36 on glucose metabolism do not wane during 
chronic treatment, which suggests that this peptide may be a novel asset in the battle against 
insulin resistance and the metabolic syndrome.  
Although PYY3-36 enhanced insulin-induced glucose disposal, it did not significantly affect 
the ability of insulin to inhibit endogenous glucose production. Nonetheless, we can not 
exclude the possibility that the experimental group size may have limited the statistical power 
necessary to detect a subtle influence of PYY3-36 on hepatic glucose metabolism. 
Alternatively, PYY3-36 exerts differential, tissue specific, effects on insulin action.  
The mechanism by which PYY3-36 affects insulin-mediated glucose metabolism remains to 
be elucidated. Perhaps, PYY3-36 modulates insulin action via the hypothalamic Y2 receptor, in 
analogy with the mechanism guiding its effects on appetite. Y2-receptor mediated inhibition 
of NPY and stimulation of POMC neuronal activity by PYY3-36 potentially reinforces insulin 
action on glucose metabolism indeed [10;11;13].  
Circulating PYY3-36 levels in fasting conditions remained below the level of detection (< 1 
pg/µl) during continuous treatment, and rose to 3.7 ± 0.8 pg/µl approximately one hour after 
i.p injection. During hyperinsulinemia (3-3.5 hours after injection), PYY3-36 levels were 
undetectable by our assay in all animals. Thus, in spite of the fact that continuous PYY3-36 
treatment did not produce measurable plasma concentrations and intermittent administration 
induced a merely transitory increase of circulating PYY3-36, both treatments significantly 
facilitated insulin mediated glucose disposal in high fat fed animals. Relatively few papers 
report plasma PYY3-36 concentrations in rodents. Postprandial levels may be in the range of 
112 pmol/L (∼ 0.4 pg/µl) and 0.18 pg/µl in freely feeding normal weight rats and mice 
respectively [14;22], whereas fasting levels are considerably lower, as PYY3-36 is primarily 
released in response to food intake [14;23]. Plasma PYY3-36 concentrations in high fat fed 
mice are unknown, but may be significantly reduced, as obese humans have clearly 
diminished circulating PYY3-36 levels [24]. Taken together, our data suggest, that even a 
relatively low dose of PYY3-36 (in view of the low circulating PYY3-36 levels during treatment) 
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can reinforce insulin action. Further dose-response experiments are warranted to evaluate 
the potential efficacy of PYY3-36 in the treatment of the metabolic syndrome. 
Food intake and body weight were not affected by PYY3-36 administration in our study. 
These findings agree with data from Challis et al., indicating that 7 days of PYY3-36 
administration did not affect food intake and body weight in POMC-/- and wild type mice [25]. 
In contrast, Batterham et al. reported that PYY3-36 acutely inhibits food intake [14], an 
observation that could not be reproduced by Tschöp and coworkers [26;27]. To take this 
issue further, we compared the acute effects of a single intraperitoneal (2.5 µg) injection of 
PYY3-36 (n = 8) or vehicle (n = 8) at 09.00 am on food intake in our animals, and found that 
cumulative food intake in 4 hours after injection was significantly inhibited by 21% in 
overnight fasted mice (P=0.028), whereas subsequent feeding over 24 hours was not 
affected by PYY3-36. These data suggest that this dose of PYY3-36 has a short-term inhibitory 
impact on food intake in overnight fasted C57BL6 mice, whereas consumption over 24 hours 
is not affected, probably as a result of a rebound compensatory increase of appetite [14;15]. 
In conclusion, the present study shows that chronic PYY3-36 administration reinforces 
insulin action on glucose disposal in mice maintained on a high fat diet, whereas it also tends 
to enhance the ability of insulin to suppress endogenous glucose production. These 
observations suggest that PYY3-36 or potential analogues may be a useful treatment for 
insulin resistance and the metabolic syndrome. 
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Aims/hypothesis. The present study was conducted to evaluate the effects of ghrelin 
on insulin's capacity to suppress endogenous glucose production (EGP) and promote 
glucose disposal (GD) in mice. To establish if the GHS-receptor can mediate the 
putative impact of ghrelin on insulin action, we also determined the metabolic effects 
of GHRP-6, a specific GHS-R agonist. In addition, we explored the biological 
significance of des-ghrelin in this experimental context. 
Methods. Vehicle, ghrelin, GHRP-6, des-ghrelin or the combination of des-ghrelin and 
ghrelin were infused i.v. for 3 hours. Simultaneously, EGP and GD were measured by 
14C-glucose dilution during a hyperinsulinaemic euglycaemic clamp. Tissue specific 
glucose uptake in muscle and adipose tissue were measured using 3H-2-deoxy-
glucose.  
Results. During hyperinsulinaemia, GD was 31% higher in ghrelin-treated mice 
compared with vehicle (77±16 vs 59±8 µmol/kg/hour respectively, P<0.05), which was 
in accordance with enhanced 2-DG uptake in muscle in ghrelin-treated animals. In 
contrast, EGP was less effectively suppressed by insulin during ghrelin infusion (by 
46±22 vs 71±11 % in controls, P<0.05). GHRP-6 did not affect insulin action. Des-
ghrelin hampered insulin's capacity to inhibit EGP, whereas it did not affect GD. The 
restraining effects of des-ghrelin and ghrelin on hepatic insulin action were abolished 
by simultaneous administration of both peptides. 
Conclusions/interpretation. Ghrelin hampers insulin's capacity to suppress EGP, 
whereas it reinforces insulin action on GD, independently of food intake and body 
weight. These metabolic effects are unlikely mediated by the GHS-receptor. 
Furthermore, simultaneous administration of des-ghrelin abolishes the inhibitory 
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INTRODUCTION 
Ghrelin is a small 28 amino acid peptide, that is primarily produced by the stomach and binds 
to the growth hormone secretagogue (GHS) receptor (GHS-R) [1;2]. It circulates in two major 
forms: n-octanoyl-ghrelin (ghrelin), which contains an n-octanoyl modification at serine-3, and 
des-octanoyl or unacylated ghrelin (des-ghrelin) [3]. Although des-ghrelin does not bind to 
the GHS-R [1;4], it may be biologically active [5].  
Ghrelin is a component of the gut-brain-axis involved in the control of energy balance. It 
stimulates food intake in rodents and man [5-8], where peak levels in plasma occur just 
before each meal and fall rapidly after re-feeding, suggesting that it serves to initiate food 
consumption [9]. To enhance appetite, ghrelin acts in the hypothalamus where it promotes 
neuropeptide Y (NPY) and orexin gene expression and inhibits pro-opiomelanocortin 
(POMC)/α-melanocyte stimulating hormone (αMSH) expression via activation of the GHS-R 
[10-16]. We recently showed that intracerebroventricular infusion of NPY hampers insulin’s 
capacity to suppress endogenous glucose production (EGP) [17], whereas central injections 
of melanotan II, a synthetic analog of αMSH, reinforces insulin action on glucose disposal 
(GD) [18]. In concert, these findings led us to hypothesize that ghrelin might adversely affect 
insulin sensitivity through activation of the GHS-R. To address this hypothesis, we 
intravenously administered vehicle, ghrelin, or growth hormone releasing peptide 6 (GHRP-6, 
a specific agonist of the GHS-R), and measured EGP and GD by 14C-glucose dilution during 
a hyperinsulinemic clamp in mice. 
Until recently, acylation of the serine-3 residue of the ghrelin molecule was believed to be 
required for bioactivity. However, recent data suggest that des-ghrelin may counteract ghrelin 
in the control of energy balance [19], and in vitro experiments revealed opposing effects of 
ghrelin and des-ghrelin on glucose production by primary hepatocytes [20]. To further 
explore the role of des-ghrelin in the regulation of fuel flux, we studied the effects of this 
peptide in the same experimental context. 
 
MATERIAL AND METHODS 
 
Animals 
Male C57BL/6J mice were housed in a temperature-controlled room on a 12-hour light-dark 
cycle, with free access to water and chow diet. All animal experiments were performed in 
accordance with the regulations of Dutch law on animal welfare and the institutional ethics 
committee for animal procedures approved the protocol. 
 




Mice were fasted for 4 hours with food withdrawn at 05.00 a.m. Hyperinsulinaemic 
euglycaemic clamp studies were started at 9.00 a.m. as described earlier [21;22]. During the 
experiments, mice were sedated with 6.25 mg/kg Acepromazine (Sanofi sante animale, 
Libourne Cedex, France) 6.25 mg/kg Midazolam (Roche, Mijdrecht, the Netherlands), and 
0.3125 mg/kg Fentanly (Janssen-Cilag, Tilburg, the Netherlands). 
Vehicle, ghrelin, or GHRP-6 (peptides from PhoenixEurope GmbH, Karlsruhe, Germany) 
were administered in a primed (0 µg, 0.6 µg, 0.26 µg) continuous (0 µg/h, 1 µg/h, 0.43 µg/h) 
i.v. infusion during the whole experiment (basal and hyperinsulinemic period). The doses of 
ghrelin, and GHRP-6 were based on previous reports [6;7;23]. First, basal rates of glucose 
production/uptake were measured by giving a primed (p) continuous (c) infusion of 14C-
glucose (p: 0.7 µCi, c: 1.2 µCi/h) (Amersham, Little Chalfont, U.K.) for 80 min. Subsequently, 
insulin was administered in a primed (4.1 mU), continuous (6.8 mU/h) i.v. infusion for 2 to 3 
hours aimed at steady state circulating insulin levels of approximately 6 ng/ml. A variable 
infusion of 12.5% D-glucose was used to maintain euglycaemia (measured via tail bleeding, 
Freestyle, TheraSense, Disetronic Medical Systems BV, Vianen, The Netherlands). Blood 
samples (75 µl) were taken during the basal period (after 60 and 80 minutes) and during the 
clamp period (when glucose levels were stable and 20 and 40 minutes later) for 
determination of plasma glucose, NEFA, insulin and 14C-glucose specific activities.  
To assess tissue-specific insulin-mediated glucose uptake, 2-deoxy-D-[3H]glucose (2-DG; 
Amersham Little Chalfont, U.K.) was administered as a bolus (1 µCi) 40 minutes before the 
end of the clamp experiment. At the end of the clamp, mice were killed, and skeletal muscle 
(hindlimb) and adipose tissue were isolated and frozen in liquid nitrogen for subsequent 
analysis.  
 
Additional studies with des-ghrelin 
In addition, a hyperinsulinaemic euglycaemic clamp study was performed while des-ghrelin 
or a combination of ghrelin en des-ghrelin were administered. Des-ghrelin, or the 
combination of ghrelin and des-ghrelin were administered in a primed (0.6 µg or 0.6 and 0.6 
µg) continuous (1 µg/h or 1 and 1 µg/h) i.v. infusion during the whole experiment (basal and 
hyperinsulinemic). The doses of des-ghrelin and the combination of ghrelin and des-ghrelin 
were based on a previous report [23]. Hyperinsulinaemic euglycaemic clamps were 
performed as stated above and randomised with these other groups. 
 
Analytical procedures  
Plasma levels of glucose and NEFA were determined using commercially available kits 
(Instruchemie, Delfzijl, The Netherlands and Wako, Neuss, Germany). Plasma insulin 
concentration was measured by a mouse insulin ELISA (Mercodia, Uppsala, Sweden). Total 
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plasma 14C-glucose was determined in 7.5 µl plasma and in supernatants after trichloroacetic 
acid (20%) precipitation and water evaporation to eliminate tritiated water.  
 
Tissue analysis  
For determination of tissue 2-DG uptake, the homogenate of muscle and adipose tissue was 
boiled, and the supernatant was subjected to an ion-change column tot separate 2-DG-6-
phosphate from 2-DG as described previously [21;24]. 
 
Calculations  
Turnover rate of glucose (µmol/min/kg) was calculated during the basal period and in steady-
state clamp conditions as the rate of tracer infusion (dpm/min) divided by the plasma specific 
activity of 14C-glucose (dpm/µmol). The ratio was corrected for body weight. During the 
hyperinsulinemic clamp EGP was calculated as the difference between the tracer-derived 
rate of glucose appearance and the glucose infusion rate. 
Tissue-specific glucose uptake in muscle and adipose tissue was calculated from tissue 2-
DG content, corrected for plasma specific activity and expressed as µmol/g tissue. 
 
Statistical analysis  
Differences between groups were determined by Kruskal-Wallis non-parametric test for k 
independent samples. When significant differences were found, Mann-Whitney non 
parametric test was used as follow-up test to determine differences between experimental 
groups and the control group. A p-value < 0.05 was considered statistically significant. All 




Plasma parameters  
Body weight, plasma glucose, NEFA and insulin concentrations in basal and 
hyperinsulinemic conditions are shown in Table 1. Body weight did not differ between the 
groups of mice. Basal glucose levels were significantly lower in the group that received 
GHRP-6 compared to the control group. Basal insulin and NEFA levels were not different 
between groups. Moreover, in steady state hyperinsulinemic conditions, plasma glucose, 
NEFA and insulin concentrations were not different between groups. 
 
Glucose turnover   
In basal conditions, EGP (and thereby whole body GD) was significantly lower in animals that 
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µmol/kg/hour, GHRP-6: 33±4 
µmol/kg/hour; p<0.01). During the 
hyperinsulinemic period, the rate of 
glucose infusion necessary to maintain 
euglycemia was significantly higher in 
animals that received ghrelin than in 
control mice (control: 91±18 µl/hour, 
ghrelin: 136±27 µl/hour, GHRP-6: 
117±31 µl/hour, p<0.01). Accordingly, 
GD rate was significantly higher in animals that received ghrelin compared to the control 
group (control: 59±8 µmol/kg/hour, ghrelin: 77±16 µmol/kg/hour, GHRP-6: 60±9 
µmol/kg/hour; p<0.05, see figure 1). In 
contrast, hyperinsulinaemia suppressed 
EGP significantly less in animals that 
received ghrelin compared to controls 
(control: 71±11 %, ghrelin: 46±22 %, 
GHRP-6: 70±22 %; p<0.05, see figure 
2). 
 
Tissue-specific glucose uptake  
Insulin-mediated 2-DG uptake in muscle 
tissue was higher in ghrelin-treated animals, compared to the control group (muscle: control: 
8.6 ± 4.4; ghrelin: 26 ± 21; GHRP-6: 7.1 ± 3.4 µmol/g tissue, p<0.05). Insulin-mediated 2-DG 
































Fig 1. Insulin mediated glucose disposal (µmol/kg/min) in 
mice that received ghrelin (n=9), GHRP-6 (n=9) or vehicle 






















Fig 2. Inhibition of EGP (%) by insulin in mice that 
received ghrelin (n=9), GHRP-6 (n=9) or vehicle (n=8). 



































































Fig 3 a) Muscle-specific glucose uptake (µmol/g) under hyperinsulinemic conditions in mice that received 
ghrelin (n=8), GHRP-6 (n=9) or vehicle (n=5). b) Adipose tissue-specific glucose uptake (µmol/g) under 
hyperinsulinemic conditions in mice that received ghrelin (n=8), GHRP-6 (n=9) or vehicle (n=5). Data are means 






control group, although this difference did not reach statistical significance (adipose tissue: 
control: 2.6 ± 1.7; ghrelin: 7.9 ± 11; GHRP-6: 3.6 ± 1.5 µmol/g tissue, p=0.09) (see figure 3a 
and b). 
 
Additional studies with des-ghrelin. 
Plasma parameters  
Body weight, plasma glucose, NEFA and insulin concentrations in basal and 
hyperinsulinemic conditions are shown in Table 1. Body weight did not differ between the 
groups of mice. Basal glucose levels were significantly lower in the group that received the 
combination of ghrelin and des-ghrelin compared to the control group. Basal insulin and 
NEFA levels were not different between groups. Moreover, in steady state hyperinsulinemic 
conditions, plasma glucose, NEFA and insulin concentrations were not different between 
groups. 
Table 2.  Glucose turnover and tissue specific glucose uptake in mice that received des-ghrelin (n=8) ghrelin and 
des-ghrelin together (n=7), or vehicle. 
 control des-ghrelin ghrelin and 
des-ghrelin 
combined 
basal EGP (µmol/kg/min) 44 ± 9 48 ± 9 27 ± 7** 
glucose infusion rate (µl/hour) 91 ± 18 70 ± 30 104 ± 19 
insulin mediated glucose disposal (µmol/kg/min) 59 ± 8 54 ± 15 50 ± 17 
inhibition of EGP (%) 71 ± 11 47 ± 13** 75 ± 21 
muscle specific glucose uptake (µmol/g tissue) 8.6 ± 4.4 11 ± 6.1 10 ± 9.1 
adipose tissue specific glucose uptake (µmol/g 
tissue) 
2.6 ± 1.7 2.6 ± 1.1 2.1 ± 1.3 
Values are expressed as means ± SD, ** p<0.01 compared to control 
 
Glucose turnover and tissue specific glucose uptake  
Basal EGP, Glucose infusion rate, insulin mediated GD, inhibition of EGP, and tissue specific 
glucose uptake are shown in Table 2. During basal conditions, EGP (and thereby whole body 
GD) was significantly lower in animals that received the combination of ghrelin and des-
ghrelin compared to the control animals. During the hyperinsulinemic period, the rate of 
glucose infusion necessary to maintain euglycemia, insulin stimulated GD, and tissue 
specific glucose uptake did not differ between the groups. In contrast, hyperinsulinaemia 
suppressed EGP significantly less in animals that received des-ghrelin compared to controls.  
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This study shows that intravenous administration of ghrelin reinforces insulin action on GD, 
whereas it hampers insulin’s capacity to inhibit EGP. In contrast, administration of GHRP-6 
did not affect insulin action. Des-ghrelin hampered insulin's capacity to inhibit EGP, whereas 
it did not affect GD. The restraining effects of des-ghrelin and ghrelin on hepatic insulin 
action were abolished by simultaneous administration of both peptides. 
The glucose infusion rate required to maintain euglycemia during insulin infusion was 
significantly higher in ghrelin treated animals, indicating that this peptide enhances whole 
body insulin sensitivity of glucose metabolism. In particular, ghrelin clearly stimulated insulin-
mediated GD as determined by tracer dilution methodology, an observation that was in line 
with enhanced 2-DG uptake in muscle and adipose tissue during hyperinsulinaemia in 
ghrelin treated animals (although statistical significance was reached only for muscle). In 
contrast, ghrelin hampered inhibition of EGP by insulin. Our results do not fully confirm our a 
priori hypothesis. As previous papers have reported that ghrelin stimulates NPY release and 
inhibits POMC/α-MSH neuronal activity in the arcuate nucleus [25], we expected to find 
ghrelin compromising insulin sensitivity of both liver and muscle/adipose tissue (we recently 
showed that central NPY hampers insulin’s action on EGP, whereas melanocortin pathways 
promote insulin mediated GD [17;18]. However, the mechanistic routes whereby ghrelin 
impacts insulin action remain to be established. Intravenously administered peptide may act 
through central pathways, but also through activation of receptors on peripheral tissues (the 
GHS-R is present in various tissues like pancreas and liver [15;26]. Indeed, ghrelin blocks 
insulin’s inhibitory effect on gene expression of key gluconeogenic enzymes in a hepatoma 
cell-line [26]. These data corroborate our own in vivo observation of ghrelin hampering insulin 
action on EGP. In contrast, i.v. administration of ghrelin appears to enhance insulin mediated 
glucose uptake, where we a priori hypothesised that it would block this action (through down-
regulation of hypothalamic α-MSH signaling [18]. It is conceivable that ghrelin acts on 
myocytes and/or adipocytes directly to stimulate GD. We are not aware of any in vitro or in 
vivo data documenting ghrelin's effects on insulin action in muscle or adipose tissue. Thus, 
further studies are required to establish if ghrelin affects insulin action via central or 
peripheral mechanisms. 
Administration of GHRP-6 did not affect insulin action. This observation agrees with a 
report indicating that, ghrelin stimulates glucose production by primary hepatocytes, but 
hexarelin does not [20], ghrelin promotes adipogenesis in bone marrow, whereas L163,255, 




novel receptor subtype [28]. In concert, these data strongly suggest that ghrelin impacts 
insulin action and metabolism via an as yet unidentified receptor. 
Des-ghrelin blocked insulin action on EGP as much as ghrelin did. In contrast, it did not 
affect insulin mediated GD. These data support the emerging view that n-octanoyl 
modification of the serine (3) residue of ghrelin is not absolutely required for bioactivity 
[19;20;23]. However, they apparently contradict a report suggesting that ghrelin and des-
ghrelin have opposing (stimulatory vs. inhibitory, respectively) effects on glucose production 
by hepatocytes [20]. The contradiction could be explained by the fact that in vitro and in vivo 
administration of des-ghrelin may have differential effects, as des-ghrelin, like ghrelin, can 
act in the brain as well as in peripheral tissues [19;27]. Co-administration of des-ghrelin 
abolished the impact of ghrelin on hepatic insulin sensitivity, which accords with an in vitro 
study showing similar results in isolated hepatocytes [20]. Our findings corroborate mounting 
evidence indicating that des-ghrelin has potentially important biological effects. The receptor 
mediating des-ghrelin bioactivity remains to be identified.  
The physiological relevance of the observed effects of ghrelin to decrease hepatic insulin 
sensitivity and increase peripheral insulin sensitivity remains to be established. Ghrelin 
secretion by (primarily) the stomach is significantly enhanced during fasting to stimulate 
appetite and initiate meal consumption [9]. In a previous study, we showed that fasting 
enhances insulin-mediated glucose uptake in mice [29]. The data we present here allow us 
to hypothesize that the rise of plasma ghrelin levels during fasting is involved in the 
physiology of this phenomenon. However, des-ghrelin concentrations clearly dominate the 
plasma profile of ghrelin-like peptides, at least in the human [30;31]. In view of the current 
evidence suggesting that des-ghrelin has metabolic effects of its own and indeed appears to 
interact with ghrelin in the control of metabolism, further studies are required to establish the 
role of ghrelin-peptides in the regulation of energy balance and fuel flux. Moreover, the 
receptor(s) mediating the metabolic signals conveyed by (des-)ghrelin need to be identified.  
In conclusion, ghrelin differentially affects tissue-specific insulin action, hampering its 
ability to inhibit EGP while reinforcing its impact on GD. These effects occur acutely and they 
are not secondary to ghrelin's well-known influence on feeding and body weight. The GHS-R 
is not likely to mediate ghrelin's metabolic effects. Des-ghrelin also appears to modulate fuel 
flux and may counteract ghrelin in the control of glucose metabolism. 
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Maintenance of plasma glucose concentration is highly important for normal body physiology, 
particularly for the central nervous system, which uses glucose as the obligatory fuel and has 
no endogenous glucose stores. The pancreatic hormone insulin is important in tightly 
regulating glucose homeostasis. Insulin inhibits endogenous glucose production and 
stimulates glucose uptake by peripheral tissues, like skeletal muscle and adipose tissue, and 
thereby lowers glucose levels. In conditions of insulin resistance, these tissues are less 
sensitive for insulin action, which is reflected in decreased inhibition of endogenous glucose 
production and decreased tissue glucose uptake at the same concentration of insulin. 
Initially, pancreatic beta cells compensate for insulin resistance by increasing insulin 
secretion. However, when this compensatory mechanism fails, hyperglycaemia and type II 
diabetes will ensue. Insulin resistance is a dominant feature in subjects with obesity and type 
II diabetes. Without treatment hyperglycaemia progresses in time, making these patients 
prone for developing secondary complications.  
 Up till now, only scarce data are available upon physiological regulation of insulin 
sensitivity by feeding status, in interaction with gastrointestinal hormones and the brain. 
Feeding status seems to impact insulin sensitivity. Recent studies showed intensive 
interactions of gut hormones and brain centres in regulating food intake. The hypothalamic 
arcuate nucleus plays a central role in this interaction. Since fine-tuning of glucose 
homeostasis is essential to survive times of scarcity, the present thesis is focussed on 
physiological modulation of insulin sensitivity, with special emphasis on the role of feeding 
status (fasting, high fat diet), gut hormones (PYY, ghrelin), brain and gut-brain interactions. 
 
Feeding status and insulin sensitivity 
During the postabsorptive state and prolonged fasting it is extremely important to keep 
glucose concentrations high enough for functioning of the brain. During fasting, adipose 
tissue lipolysis increases, resulting in increased supply of FFA to the liver and muscle. In the 
liver and muscle, FFA can either be used for β-oxidation or TG storage. By β-oxidation, the 
liver transforms FFA in ketone bodies, which can be used as energy source by the brain. If 
tissue FFA uptake exceeds β-oxidation, excessive TG storage will be the consequence. In 
obesity, increased FFA concentrations and excessive tissue TG storage are associated with 
tissue insulin resistance. Fatty acid derivatives are ligands for nuclear transciption factors like 
PPARs and SREBPs, which alter the expression of enzymes/proteins involved in glucose 
and lipid metabolism and thus  interact with insulin effects. The impact of fasting on tissue 
insulin sensitivity is unknown. Therefore, we studied the effects of 16 hours of fasting 
(prolonged fasting) versus 4 hr of fasting (postprandial state) on hepatic and muscle insulin 
sensitivity in wild-type mice in vivo in relation to tissue TG accumulation and changes in 
mRNA expression of transcription factors and related proteins involved in glucose and lipid 
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metabolism (chapter 2). Whole-body and hepatic insulin sensitivity were measured by 
hyperinsulinaemic euglycaemic clamp in combination with D-[14C]glucose infusion. Tissue 
specific insulin sensitivity was measured by use of 2-deoxy-D[3H]glucose. Sixteen hr of 
fasting did not impact hepatic insulin sensitivity in terms of glucose production in the 
presence of increased hepatic triglyceride content (71±19 versus 12±7 µg/mg protein, 
p<0.01). In muscle, however, fasting resulted in increased insulin sensitivity with increased 
muscle glucose uptake (4.0±2.6 versus 1.3±0.3 % glucose uptake/ g tissue, p<0.01) without 
changes in muscle triglyceride content (25±7 versus 29±13 µg/mg protein, ns). In the liver, 
fasting resulted in increased mRNA expression of genes promoting gluconeogenesis (PGC1 
and PEPCK) and triglyceride synthesis (PPARγ, DGAT1 and DGAT2), but in decreased 
mRNA expression of genes involved in glycogenolysis (GP) and fatty acid synthesis 
(SREBP1c, FAS and ACC1). In muscle, increased mRNA expression of genes promoting 
glucose uptake (PGC1 and GLUT-4), as well as lipogenesis (PPARγ, FAS, ACC1, DGAT-1 
and -2) and β-oxidation (PPARα) was found. We conclude from this study that 16 hours of 
fasting does not induce hepatic insulin resistance, although it causes liver steatosis, whereas 
muscle insulin sensitivity increases without changes in muscle triglyceride content. 
Therefore, fasting induces differential changes in tissue-specific insulin sensitivity and liver 
and muscle TG content are unlikely to be involved in these changes.  
With regard to the physiological relevance of the increase in muscle insulin sensitivity 
during fasting, a state dominated by low insulin levels, it can be speculated that this 
mechanism might serve as an extremely efficient manner to prepare peripheral tissues 
metabolically to shift to glucose uptake, when the next meal arrives and insulin levels 
increase, thereby preventing glucose peaks after meals.    
 
High fat feeding, insulin sensitivity and the brain 
At present, the western type of diet contains too much fat. This high fat diet is a risk factor for 
overweight, insulin resistance, and, thereby, for type II diabetes. Studies in rats and dogs on 
a high fat diet show the induction of hepatic insulin resistance as an early event, followed by 
muscle insulin resistance (1;2). The arcuate nucleus integrates a multitude of behavioural 
and metabolic adaptations to food intake and starvation, necessary to maintain fuel 
homeostasis despite profound environmental variations in nutrient availability. Two types of 
neurons in the arcuate nucleus of the hypothalamus are of major importance for the control 
of these processes: the orexigenic neurons co-expressing AgRP and NPY, and the 
anorexigenic neurons expressing POMC/ α-MSH. α-MSH binds to and stimulates 




involvement of the arcuate NPY/POMC circuitry in the modulation of insulin sensitivity, in 
addition to its impact on food intake. 
 
The impact of a high fat diet on tissue specific insulin sensitivity in mice and triglyceride 
accumulation in relation to changes in mRNA expression levels of NPY, POMC, AgRP and 
CART in the hypothalamus is unknown. Therefore, we studied the effects of a 2 weeks high 
fat diet in wildtype mice on these parameters (chapter 3). Whole-body and hepatic insulin 
sensitivity were measured by hyperinsulinaemic-euglycaemic clamp in combination with D-
[14C]glucose infusion. Tissue specific insulin sensitivity was measured by use of 2-deoxy-
D[3H]glucose. Two weeks of high fat diet did show hepatic insulin resistance with regard to 
inhibition of hepatic glucose production (35±20% versus 61±23%, p<0.05) and in the 
presence of increased hepatic TG accumulation (32 ±10 versus 12±6 µg/mg protein, p<0.05). 
Under hyperinsulinemic conditions, whole body glucose uptake was not different between the 
HF fed group and the control group (66±10 µmol/kg.min versus 59±8 µmol/kg.min, ns), also 
reflected by unaltered muscle-specific glucose uptake in the HF fed group compared to the 
control group (1.3±0.6 versus 1.3±0.3% per g tissue). Muscle TG content was not 
significantly different either (27±9 versus 23±7 µg/mg protein, ns). We did not observe 
changes in hypothalamic mRNA expression levels of NPY, AgRP, POMC and CART after 2 
weeks of high fat diet compared to control mice.  
From this study, we conclude that 2 weeks of high fat feeding in mice does not affect 
mRNA expression levels of NPY, AgRP, POMC or CART in the whole hypothalamus, despite 
induction of hepatic, but not peripheral, insulin resistance. Since in our study mRNA levels 
were measured in whole hypothalamus without regional assessment within the different 
nuclei, we cannot exclude involvement of certain specific hypothalamic area's in the 
regulation of hepatic insulin resistance during a high fat diet. In addition, we did not measure 
the expression levels of the relevant peptide levels. Additional studies have to be performed 
to evaluate the potential role of the respective nuclei within the hypothalamus in mediating 
peripheral insulin sensitivity during high fat feeding.  
 
In addition to the impact of NPY on food intake, icv administration of NPY acutely hampers 
the capacity of insulin to inhibit hepatic glucose production. The POMC pathway also seems 
to be involved in regulating insulin sensitivity. Chronic (7 days) icv infusion of α-MSH 
enhanced peripheral and hepatic insulin sensitivity in rats (3) and POMC gene 
overexpression ameliorates insulin resistance in leptin-deficient mice (4). In the latter studies, 
the effects on insulin sensitivity occur in the presence of a concomitant reduction in food 
intake and fat mass, which precludes distinction of putative direct effects of POMC/α-MSH on 
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insulin sensitivity from indirect effects via feeding and body composition. To document the 
direct effects of activation of MC3/4 receptors on insulin sensitivity, we injected melanotan II 
(MTII), an agonist of these MC3/4 receptors icv, and quantified hepatic and peripheral insulin 
sensitivity of glucose metabolism in mice without access to food (chapter 4). We performed 
this study in 24 hour fasted mice, which received 3 times an icv injection with MTII during this 
period of time. Whole-body and hepatic insulin sensitivity were measured by 
hyperinsulinaemic euglycaemic clamp in combination with D-[3H]glucose infusion. A real time 
polymerase chain reaction (RT-PCR) was used to measure mRNA expression levels of 
GLUT-4 in skeletal muscle. Hepatic insulin sensitivity was unaltered as hyperinsulinaemia 
suppressed hepatic glucose production to a similar extent in MTII- vs. vehicle-treated 
animals (45 ± 27% vs. 50 ± 20%, ns). However, glucose disposal rate was significantly 
higher in MTII treated animals (151 ± 20 vs. 108 ± 20 µmol/min/kg, resp., p<0.01), in the 
presence of increased GLUT-4 mRNA expression in skeletal muscle in the MTII treated 
group compared to vehicle-treated mice (307 ± 94 vs. 100 ± 56 %, p<0.01).  
In conclusion, this study shows that activation of central melanocortin-3/4 receptors by 
MTII enhances insulin sensitivity of whole body glucose disposal, independently of food 
intake and fat mass, whereas it does not affect insulin's ability to suppress EGP. These 
observations are in line with the emerging notion, that neural circuits, apart from their effects 
on feeding, modulate insulin sensitivity to adapt metabolic conditions in the face of 
environmental fluctuations in nutrient availability. 
  
Gastrointestinal hormones and insulin sensitivity 
Gastrointestinal hormones vary according to feeding status and are known to affect food 
intake. For instance, PYY3-36 concentration is low during fasting and increased in the fed 
state, whereas ghrelin concentration is high after fasting, and peaks just before a meal. 
Accordingly, PYY3-36 inhibits food intake whereas ghrelin stimulates food intake. 
Gastrointestinal hormones are known to influence appetite by regulating neuropeptides in the 
hypothalamus. As these neuropeptides can affect insulin sensitivity, gastrointestinal 
hormones might be involved in regulating insulin sensitivity as well.  
 
PYY3-36 
In view of the fact that PYY3-36 inhibits NPY- and activates POMC neuronal activity, we 
wondered whether PYY3-36 can improve insulin sensitivity independently of its effects on food 
intake and body weight. Therefore, we infused PYY3-36 intravenously and quantified glucose 
and lipid metabolism during a hyperinsulinemic euglycemic clamp in mice that were fed a 
high fat diet for 2 weeks (chapter 5). To measure insulin sensitivity of hepatic and peripheral 




glucose and 2-deoxy-glucose was performed. To measure insulin sensitivity of FFA 
metabolism, a hyperinsulinaemic euglycaemic clamp, in combination with 14C-palmitate was 
performed. PYY3-36 enhanced insulin-induced glucose disposal (103.8 ± 10.9 vs. 76.1 ± 11.4 
µmol/min/kg, respectively, p=0.001). Accordingly, 2-DG uptake in muscle and adipose tissue 
in hyperinsulinaemic conditions was higher during PYY3-36 infusion, although the difference 
with control reached statistical significance only for muscle (2.1 ± 0.5 vs. 1.5 ± 0.5 %/ g 
tissue, p<0.05). In contrast, PYY3-36 did not significantly impact insulin’s capacity to inhibit 
endogenous glucose production (62 ± 29 vs. 42 ± 18%, ns). Insulin action on FFA 
metabolism was not affected by PYY3-36 either, as indicated by similar lipolysis rates during 
hyperinsulinaemia (22.4 ± 12.3 vs. 21.3 ± 10.9 µmol/min/kg, ns) in PYY3-36 and saline infused 
animals. In conclusion, this study shows that PYY3-36 reinforces insulin action in mice 
maintained on a high fat diet, independent of its effects on food intake and body weight. In 
this context, PYY3-36 appears to predominantly impact insulin mediated glucose disposal, 
whereas it leaves insulin action on glucose production largely unaffected. These data 
suggest that PYY3-36 or synthetic analogues of this peptide may be valuable assets to our 
armamentarium of drugs designed to battle insulin resistance and type II diabetes mellitus. 
 The value of PYY3-36 as a new drug depends on the duration of its effects. Therefore, we 
investigated the long-term effects of PYY3-36 (administration of 7 days either continuously via 
subcutaneous mini-pumps or intermittent via subcutaneous injections once a day) on insulin 
sensitivity (chapter 6). Whole-body and hepatic insulin sensitivity were measured by 
hyperinsulinaemic euglycaemic clamp in combination with D-[14C]glucose infusion. Tissue 
specific insulin sensitivity was measured by use of 2-deoxy-D[3H]glucose. Long term PYY3-36 
administration did not seem to have any adverse or counterregulating effects, as long term 
administration showed the same effect as acute administration: increased peripheral insulin 




As ghrelin acts in the hypothalamus where it promotes NPY and orexin gene expression and 
inhibits POMC/αMSH expression via activation of the GHS-receptor, we wondered whether 
ghrelin might affect insulin sensitivity via the GHS-receptor. To address this hypothesis, we 
intravenously administered vehicle, ghrelin, or growth hormone releasing peptide 6 (GHRP-6, 
a specific agonist of the GHS-R), and measured insulin sensitivity in wildtype mice (chapter 
7). Until recently, acylation of the serine-3 residue of the ghrelin molecule was believed to be 
required for bioactivity. However, recent data suggest that des-ghrelin may counteract ghrelin 
in the control of energy balance (5), and in vitro experiments revealed opposing effects of 
ghrelin and des-ghrelin on glucose production by primary hepatocytes (6). To further explore 
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the role of des-ghrelin in the regulation of fuel flux, we studied the effects of this peptide in 
the same experimental context. Whole-body and hepatic insulin sensitivity were measured by 
hyperinsulinaemic euglycaemic clamp in combination with D-[14C]glucose infusion. Tissue 
specific insulin sensitivity was measured by use of 2-deoxy-D[3H]glucose. Hyperinsulinaemia 
suppressed EGP significantly less in animals that received ghrelin compared to controls 
(control: 71±11 %, ghrelin: 46±22 %, GHRP-6: 70±22 %; p<0.05). In contrast, glucose 
disposal rate was significantly higher in animals that received ghrelin compared to the control 
group (control: 59±8 µmol/kg/hour, ghrelin: 77±16 µmol/kg/hour, GHRP-6: 60±9 
µmol/kg/hour; p<0.05), in accordance with insulin-mediated 2-DG uptake in muscle and 
adipose tissue, which was higher in ghrelin-treated animals, compared to the control group 
(muscle: control: 8.6 ± 4.4; ghrelin: 26 ± 21; GHRP-6: 7.1 ± 3.4 µmol/g tissue, p<0.05) 
although this difference did not reach statistical significance in adipose tissue (adipose 
tissue: control: 2.6 ± 1.7; ghrelin: 7.9 ± 11; GHRP-6: 3.6 ± 1.5 µmol/g tissue, p=0.09). With 
regard to des-ghrelin, during the hyperinsulinaemic period, insulin stimulated glucose 
disposal and tissue specific glucose uptake did not differ from the control group. In contrast, 
hyperinsulinaemia suppressed hepatic glucose production significantly less in animals that 
received des-ghrelin compared to controls (47±13 versus 71±11 %, p<0.01). In conclusion, 
ghrelin differentially affects tissue-specific insulin action, hampering its ability to inhibit 
endogenous glucose production while reinforcing its impact on glucose disposal. These 
effects occur acutely and they are not secondary to ghrelin's well-known influence on feeding 
and body weight. The GHS-R is not likely to mediate ghrelin's metabolic effects. Des-ghrelin 
also appears to modulate fuel flux and may counteract ghrelin in the control of glucose 
metabolism.   
 
Conclusions  
The hypothalamic arcuate nucleus has a central role in the regulation of appetite and food 
intake. During fasting, expression of neuropeptides involved in the regulation of food intake in 
the arcuate nucleus change: expression of the orexigenic neuropeptide NPY increases, 
whereas expression of the anorexigenic neuropeptide POMC decreases, resulting in 
stimulation of food intake. Under fed conditions, expression of POMC increases, whereas 
expression of NPY decreases, resulting in a inhibition of food intake.  
 Recent studies showed that the brain regulates appetite and food intake in crosstalk with 
the gut. Secretion of gastrointestinal hormones varies according to feeding status. During 
fasting, secretion of ghrelin, an activator of NPY neurons and inhibitor of POMC neurons, 
increases,  whereas secretion of PYY3-36, an agonist of the presynaptic NPY Y2 receptor and 
thereby inhibitor of NPY neurons and activator of POMC neurons, decreases, resulting in 




Until recently, it was thought that regulation of glucose metabolism was the result of crosstalk 
between the liver, muscle and adipose tissue with the pancreas and adrenals, producing 
glucoregulatory hormones, with a central role for insulin. Recent studies, however, changed 
this “peripheral” view to a more “central” concept with a prominent role for the brain 
regulating glucose homeostasis. Recent studies of Rossetti et al. showed that chronic 
blockade of hypothalamic insulin receptor signalling caused hepatic insulin resistance of 
glucose production, whereas acute depletion of insulin receptors in the liver failed to alter the 
effect of physiological hyperinsulinemia on the rate of glucose production (7-9). These 
studies show that brain insulin action is required for intact glucose homeostasis. 
 The studies performed in this thesis show that the brain not only regulates food intake but 
also insulin sensitivity of glucose metabolism in liver and peripheral tissues, like skeletal 
muscle and adipose tissue (see figure 1), dependently and independently of feeding status 
and likely via related changes in gastrointestinal hormones. In this way, at every moment, 
tissue insulin sensitivity can be fine-tuned, dependently and independently of feeding status. 
We showed that fasting itself resulted in an increase in muscle insulin sensitivity. Since 
intravenous administration of ghrelin in mice was shown to increase muscle insulin sensitivity 
as well, it can be speculated that the effects of fasting on peripheral insulin sensitivity are 
mediated by increased secretion of ghrelin, probably (partly) in crosstalk with the arcuate 
nucleus NPY/POMC neuronal circuitry. Interestingly, all intervention studies performed by 
others and in this thesis showed tissue specific effects of the different interventions on insulin 
sensitivity. Van den Hoek et al. showed that central infusion of NPY decreased insulin action 
on hepatic glucose production, without affecting peripheral insulin sensitivity (10). Central 
injections of MTII (stimulating the POMC pathway) resulted in an increase in peripheral 
glucose disposal without affecting hepatic insulin sensitivity. Intervenous administration of 
ghrelin increased muscle insulin sensitivity but decreased hepatic insulin sensitivity. 
Intravenous infusion of PYY3-36 increased peripheral insulin sensitivity as well, but had no 
impact on hepatic insulin sensitivity. Since, for example, fasting and ghrelin increase 
peripheral insulin sensitivity whereas NPY, which is also activated by fasting and ghrelin, has 
no effect on peripheral insulin sensitivity but induces hepatic insulin resistance, the effects of 
fasting and ghrelin on peripheral insulin sensitivity cannot merely be explained by modulation 
of NPY neurons. In contrast, the induction of hepatic insulin resistance by ghrelin might be 
(partly) the result of activation of NPY neurons by ghrelin.   
 Although it has been shown by others that regulation of food intake by gastrointestinal 
hormones is mediated by the brain, this remains speculative for the regulation of body insulin 
sensitivity. Receptors for gastrointestinal hormones are found throughout the body, both 
centrally and peripherally. From the studies in this thesis no conclusions can be drawn about 
the site of action of gastrointestinal hormones in the central nervous system. Therefore, more 
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research, like peripheral and central administration of gastrointestinal hormones in 
combination with blockers of the NPY/POMC system and denervation studies, is needed to 
draw conclusions about the contribution of the brain and site of action in the brain with regard 
to the regulation of insulin sensitivity due to changes in gastrointestinal hormone levels.  
As the brain uses glucose as the obligatory fuel, the regulation of feeding and insulin 
sensitivity is of major importance to the brain. It is therefore not surprising that the brain itself 












































Figure 1. A role for
gastrointestinal 
hormones and the
brain in the regulation
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Het handhaven van constante glucose spiegels in het bloed is erg belangrijk voor de normale 
lichaamsfysiologie en in het bijzonder voor het centrale zenuwstelsel dat glucose als 
noodzakelijke brandstof gebruikt en geen endogene glucose voorraad heeft. Het hormoon 
insuline, uitgescheiden door de alvleesklier, is belangrijk bij het nauwkeurig reguleren van de 
glucose homeostase. Insuline remt de endogene glucose productie en stimuleert de glucose 
opname door perifere weefsels, zoals spier- en vetweefsel, en verlaagt daardoor glucose 
spiegels. In het geval van insuline resistentie zijn deze weefsels minder gevoelig voor de 
werking van insuline, wat gereflecteerd wordt door een verminderde remming van de 
endogene glucose productie en een verminderde remming van de glucose opname in de 
periferie bij gelijke insuline concentraties. In het begin zullen de beta cellen van de 
alvleesklier compenseren voor de insuline resistentie door de insuline secretie te verhogen. 
Echter, wanneer dit compensatoire mechanisme faalt, zullen hyperglycemie en type II 
diabetes volgen. Insuline resistentie is een dominant kenmerk van mensen met obesitas en 
type II diabetes. Zonder behandeling zal de hyperglycemie verergeren in de tijd, wat deze 
patienten gevoelig maakt voor het ontwikkelen van secundaire complicaties. 
Tot nu toe is er slechts een schaarse hoeveelheid data beschikbaar over de fysiologische 
regulatie van insuline gevoeligheid door voedingsstatus in interactie met gastrointestinale 
hormonen en de hersenen. De voedingsstatus lijkt effect te hebben op insuline gevoeligheid. 
Recente studies hebben intensieve interacties tussen darmhormonen en hersenkernen in de 
regulatie van voedselinname laten zien. De nucleus arcuatus in de hypothalamus lijkt hier 
een centrale rol bij te spelen. Aangezien nauwkeurige regulatie van de glucose homeostase 
essentieel is in tijden van voedselschaarste, hebben we ons in dit proefschrift 
geconcentreerd op de fysiologische modulatie van insuline gevoeligheid, met speciale 
aandacht voor de rol van voedingsstatus (vasten, hoog vet dieet), darmhormonen (PYY, 
ghrelin), de hersenen en darm-brein interacties. 
 
Voedsel status en insuline gevoeligheid 
Tijdens de nuchtere staat en langdurig vasten is het extreem belangrijk om glucose spiegels 
hoog genoeg te houden om de hersenen te laten functioneren. Tijdens vasten stijgt de 
lipolyse in vetweefsel, wat resulteert in een verhoogde toevoer van vrije vetzuren naar de 
lever en spierweefsel. In lever en spierweefsel kunnen de vetzuren of gebruikt worden voor 
β-oxidatie of worden opgeslagen als triglyceriden. In het geval van β-oxidatie transformeert 
de lever de vetzuren in ketonen, die als energiebron kunnen worden gebruikt door de 
hersenen. Als de vetzuuropname groter is dan de β-oxidatie, zal een buitensporige 
triglyceriden-opslag de consequentie zijn. Bij obesitas zijn verhoogde vetzuurconcentraties 
en overmatige triglyceridenopslag geassocieerd met insuline resistentie. Vetzuurderivaten 
zijn liganden voor transcriptiefactoren zoals PPARs en SREBPs, die bekend staan om hun 
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vermogen de expressie van enzymen/eiwitten betrokken bij het glucose en lipiden 
metabolisme te veranderen. Deze transcriptiefactoren hebben effecten op de insuline 
gevoeligheid. Het effect van vasten op weefsel-specifieke insuline gevoeligheid was 
onbekend. Daarom hebben we de effecten bestudeerd van 16 uur vasten (langdurig vasten) 
versus 4 uur vasten (postprandiaal) op insuline gevoeligheid van lever en spier in wildtype 
muizen in vivo, in relatie met weefsel-specifieke triglyceridenstapeling en met veranderingen 
in mRNA expressie van transcriptie factoren en gerelateerde eiwitten betrokken bij glucose 
en lipiden metabolisme (hoofdstuk 2). Totale en lever-specifieke insuline gevoeligheid 
werden gemeten met behulp van een hyperinsulinemische euglycemische clamp, in 
combinatie met D-[14C]glucose infusie. Voor het meten van weefsel-specifieke insuline 
gevoeligheid werd gebruik gemaakt van 2-deoxy-D-[3H]glucose. Zestien uur vasten had geen 
effect op de hepatische insuline gevoeligheid met betrekking tot de glucose productie in de 
aanwezigheid van een verhoogde triglyceridenstapeling in de lever (71±19 versus 12±7 
µg/mg eiwit, p<0.01). In spier echter, resulteerde vasten in een verhoogde insuline 
gevoeligheid met verhoogde glucose opname door de spier (4.0±2.6 versus 1.3±0.3 % 
glucose opname/g weefsel, p<0.01), zonder veranderingen van triglyceride inhoud in 
spierweefsel (25±7 versus 29±13 µg/mg eiwit, ns). In de lever resulteerde vasten in 
verhoogde mRNA expressies van genen die de gluconeogenese (PGC1 en PEPCK) en 
triglyceride synthese (PPARγ, DGAT1 and DGAT2) promoten, maar in verlaagde mRNA 
expressies van genen die betrokken zijn bij glycogenolyse (GP) en vetzuursynthese 
(SREBP1c, FAS en ACC1). In spier resulteerde vasten in verhoogde mRNA expressies van 
genen die glucose opname (PGC1 en GLUT-4), als ook lipogenese (PPARγ, FAS, ACC1, 
DGAT-1 and -2) en β-oxidatie (PPARα) promoten. We concluderen uit deze studie dat 16 uur 
vasten geen hepatische insuline resistentie induceert, ondanks het veroorzaken van lever 
steatose, terwijl spier-specifieke insuline gevoeligheid verbetert zonder veranderingen in 
triglyceridenstapeling in de spier. Vasten induceert dus differentiële veranderingen in 
weefsel-specifieke insuline gevoeligheid en het is onwaarschijnlijk dat triglyceriden stapeling 
in lever en spier betrokken zijn bij deze veranderingen. Met betrekking tot de fysiologische 
relevantie van de verbetering van de spier-specifieke insuline gevoeligheid tijdens vasten, 
kunnen we speculeren dat dit mechanisme zou kunnen dienen als een extreem efficiënte 
manier om de perifere weefsels metabool gezien voor te bereiden op glucose opname zodra 
de volgende maaltijd komt en insuline spiegels gaan stijgen, om op deze manier glucose 
pieken na een maaltijd te voorkomen. 
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Hoog vet dieet, insuline gevoeligheid en de hersenen 
Het westerse type dieet in onze huidige tijd bevat te veel vet. Dit hoog vet dieet is een 
risicofactor voor het krijgen van overgewicht, insuline resistentie en dus voor type II diabetes. 
Studies in ratten en honden op een hoog vet dieet laten de inductie van hepatische insuline 
resistentie als een vroege consequentie zien, wat later gevolgd wordt door insuline 
resistentie in de spier (1;2). De nucleus arcuatus integreert een groot aantal gedrags- en 
metabole aanpassingen aan voedselinname en gebrek aan voeding, wat nodig is om de 
energie homeostase te handhaven ondanks variaties in de beschikbaarheid van voedsel. 
Twee types neuronen in de nucleus arcuatus in hypothalamus zijn hoogst belangrijk voor de 
controle van deze processen: de eetluststimulerende neuronen die zowel AgRP als NPY tot 
uiting brengen, en de eetlustremmende neuronen die POMC/α-MSH tot uiting brengen. α-
MSH bind aan en stimuleert melanocortine (MC) receptoren. Recente data van andere 
groepen en ook onze groep, laat zien dat het NPY/POMC circuit in de nucleus arcuatus 
betrokken is bij de modulatie van insuline gevoeligheid, onafhankelijk van de effecten van 
NPY/POMC op voedselinname.  
 
Het effect van een hoog vet dieet op weefsel-specifieke insuline gevoeligheid in muizen en 
triglyceridenstapeling, in relatie tot veranderingen in mRNA expressie van NPY, POMC, 
AgRP en CART in de hypothalamus is onbekend.  Wij bestudeerden daarom de effecten 
hierop van 2 weken hoog vet dieet in wildtype muizen (hoofdstuk 3). Totale en lever-
specifieke insuline gevoeligheid werden gemeten met behulp van een hyperinsulinemische 
euglycemische clamp, in combinatie met D-[14C]glucose infusie. Voor het meten van weefsel-
specifieke insuline gevoeligheid werd gebruik gemaakt van 2-deoxy-D-[3H]glucose. Twee 
weken hoog vet dieet liet hepatische insuline resistentie met betrekking tot de remming van 
de hepatische glucose productie zien (35±20% versus 61±23%, p<0.05), in de aanwezigheid 
van verhoogde triglyceridenstapeling in de lever (32 ±10 versus 12±6 µg/mg eiwit, p<0.05). 
Tijdens hyperinsulinemische omstandigheden was de totale glucose opname niet 
verschillend tussen de hoog vet gevoede groep en de controle groep (66±10 µmol/kg.min 
versus 59±8 µmol/kg.min, ns), wat ook gereflecteerd werd door een onverandere spier-
specifieke glucose opname in de hoog vet gevoede groep vergeleken met de controle groep 
(1.3±0.6 versus 1.3±0.3% per g tissue). We zagen geen veranderingen in hypothalame 
mRNA expressies van NPY, AgRP, POMC en CART in muizen na 2 weken hoog vet dieet 
vergeleken met controle muizen. 
Uit deze studie kunnen we concluderen dat 2 weken hoog vet dieet in muizen mRNA 
expressies van NPY, AgRP, POMC of CART in de hele hypothalamus niet beinvloedt, 
ondanks inductie van hepatische, maar niet perifere, insuline resistentie. Omdat in onze 
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studie mRNA expressies gemeten zijn in de gehele hypothalamus zonder regionale dissectie 
van de verschillende kernen, kunnen we de betrokkenheid van specifieke hypothalame 
kernen in de regulatie van hepatische insuline resistentie tijdens een hoog vet dieet niet 
totaal excluderen. Bovendien hebben we geen expressie niveaus van relevante eiwitten 
gemeten. Meer onderzoek is nodig om de mogelijke rol van de verschillende specifieke 
hypothalame kernen bij de regulatie van insuline gevoeligheid tijdens hoog vet diet te 
evalueren.  
 
Naast effecten op voedselinname, belemmert icv toediening van NPY ook acuut de 
capaciteit van insuline om de hepatische glucose productie te remmen. POMC lijkt ook 
betrokken te zijn bij de regulatie van insuline gevoeligheid. Chronische (7 dagen) icv infusie 
van α-MSH verbetert perifere en hepatische insuline gevoeligheid in ratten (3) en POMC 
overexpressie verbetert insuline resistentie in leptine deficiente muizen(4). In deze laatste 
studies doen de effecten op insuline gevoeligheid zich voor in de aanwezigheid van een 
begeleidende reductie in voedselinname en vetmassa, wat het maken van een onderscheid 
tussen vermeende directe effecten van POMC/α-MSH op insuline gevoeligheid en indirecte 
effecten via voedselinname en lichaamscompositie belet. Om de directe effecten van 
activatie van MC3/4 receptoren op de insuline gevoeligheid te documenteren, injecteerden 
we melanotan II (MTII), een agonist van deze MC3/4 receptoren, icv en kwantificeerden we 
hepatische en perifere insuline gevoeligheid van het glucose metabolisme in muizen zonder 
toegang tot voedsel (hoofdstuk 4). We hebben deze studie uitgevoerd in 24 uur gevaste 
muizen, die gedurende deze periode 3 keer een icv injectie kregen met MTII. Totale en lever-
specifieke insuline gevoeligheid werden gemeten met behulp van een hyperinsulinemische 
euglycemische clamp, in combinatie met D-[3H]glucose infusie. Een real-time PCR werd 
gebruikt om mRNA expressie van GLUT4 in spierweefsel te meten. Hepatische insuline 
gevoeligheid was onveranderd, aangezien hyperinsulinemie de hepatische glucose productie 
van MTII- en vehicle behandelde muizen met gelijke hoeveelheid remde (45 ± 27% vs. 50 ± 
20%, ns). De glucose opname snelheid was echter significant hoger in MTII behandelde 
muizen (151 ± 20 vs. 108 ± 20 µmol/min/kg, resp., p<0.01), in aanwezigheid van een 
verhoogde GLUT4 mRNA expressie in spier in de MTII behandelde groep vergeleken met de 
controle groep  (307 ± 94 vs. 100 ± 56 %, p<0.01).  
Uit deze studie kunnen we concluderen dat activatie van centrale MC3/4 receptoren door 
MTII zorgt voor een verbetering van de insuline gevoeligheid met betrekking tot de totale 
glucose opname, onafhankelijk van voedselinname en lichaamsgewicht, terwijl er geen effect 
is op het vermogen van insuline om de endogene glucose productie te remmen. Deze 
observaties komen overeen met het concept dat steeds meer naar voren komt, dat neurale 
circuits, naast effecten op voedselinname, insuline gevoeligheid moduleren om metabole 
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condities aan te passen in het aangezicht van fluctuaties in beschikbaarheid van 
voedingmiddelen. 
 
Gastrointestinale hormonen en insuline gevoeligheid  
Gastrointestinale hormonen variëren afhankelijk van voedingsstatus en staan bekend om 
hun effect op voedselinname. Ter illustratie, PYY3-36 concentraties zijn laag tijdens vasten en 
verhoogd in de gevoede staat, terwijl ghrelin concentraties hoog zijn na vasten en net voor 
de maaltijd pieken. Dienovereenkomstig remt PYY3-36 voedselinname, terwijl ghrelin 
voedselinname stimuleert. Van gastrointestinale hormonen is bekend dat ze de eetlust 
kunnen beinvloeden door de regulatie van neuropeptides in de hypothalamus. Aangezien 
deze neuropeptides insuline gevoeligheid kunnen beïnvloeden, zouden gastrointestinale 
hormonen ook betrokken kunnen zijn bij de regulatie van insuline gevoeligheid. 
 
PYY3-36 
Aangezien PYY3-36 de neuronale activiteit van NPY remt en die van POMC stimuleert, 
vroegen we ons af of PYY3-36 insuline gevoeligheid kan verbeteren, onafhankelijk van de 
effecten op voedselinname en lichaamsgewicht. Daarom hebben we PYY3-36 intraveneus 
geinfuseerd en het glucose en lipidenmetabolisme gekwanitficeerd tijdens een 
hyperinsulinemische euglycemische clamp in muizen die 2 weken een hoog vet dieet hadden 
gegeten (hoofdstuk 5). Om insuline gevoeligheid met betrekking tot het glucose 
metabolisme van de lever en de periferie te meten werd een hyperinsulinemische 
euglycemische clamp, in combinatie met radioactief gelabeld glucose en 2-deoxy-glucose, 
uitgevoerd. Om de insuline gevoeligheid met betrekking tot het vetzuurmetabolisme te meten 
werd ook een hyperinsulinemische euglycemische clamp, in combinatie met 14C palmitaat, 
uitgevoerd. PYY3-36 verbeterde de door insuline geinduceerde glucose opname (103.8 ± 10.9 
vs. 76.1 ± 11.4 µmol/min/kg, respectievelijk, p=0.001). Dienovereenkomstig was glucose  
opname in spier en vetweefsel tijdens hyperinsulinemische condities hoger gedurende PYY3-
36 infusie, hoewel het verschil met de controle groep alleen statistische significantie bereikte 
voor spierweefsel (2.1 ± 0.5 vs. 1.5 ± 0.5 %/ g tissue, p<0.05). Daartegenover had PYY3-36 
geen effect op de capaciteit van insuline om de endogene glucose productie te remmen (62 
± 29 vs. 42 ± 18%, ns). PYY3-36 had ook geen effect op actie van insuline met betrekking tot 
het vetzuur metabolisme, wat aangeduid werd door gelijke lipolyse snelheden gedurende 
hyperinsulinemie (22.4 ± 12.3 vs. 21.3 ± 10.9 µmol/min/kg, ns) in dieren die met PYY3-36 of 
vehicle zijn geinfuseerd. Uit deze studie kunnen we concluderen dat PYY3-36 de actie van 
insuline versterkt in muizen die op hoog vet dieet gehouden zijn, onafhankelijk van zijn 
effecten op voedselinname en lichaamsgewicht. In deze context blijkt PYY3-36 voornamelijk 
effect te hebben op insuline gemedieerde glucose opname, terwijl het de actie van insuline 
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op de glucose productie grotendeels onbeinvloed laat. Deze data suggereren dat PYY3-36 of 
synthetische analogen van dit eiwit waardevolle middelen zijn in de strijd tegen insuline 
resistentie en type II diabetes mellitus. 
 De waarde van PYY3-36 als een nieuw geneesmiddel hangt af van de duur van zijn 
effecten. Daarom hebben we onderzoek gedaan naar de lange termijn effecten van PYY3-36 
(toediening gedurende 7 dagen, of continu via subcutane minipompjes of intermitterend via 
subcutane injectie eenmaal per dag) op insuline gevoeligheid (hoofdstuk 6). Totale en lever-
specifieke insuline gevoeligheid werden gemeten met behulp van een hyperinsulinemische 
euglycemische clamp, in combinatie met D-[14C]glucose infusie. Weefsel specifieke insuline 
gevoeligheid werd gemeten met behulp van 2-deoxy-D[3H] glucose infusie. Lange termijn 
toediening van PYY3-36 leek geen nadelige of counterregulatoire effecten te hebben, 
aangezien lange termijn toediending dezelfde effecten liet zien als acute toediening, namelijk 
verhoogde perifere insuline gevoeligheid. Opmerkelijk genoeg was er geen verschil tussen 
continue en intermitterende toediening. 
 
Ghrelin 
Aangezien ghrelin zijn werking heeft in de hypothalamus, waar het NPY en orexine expressie 
stimuleert en POMC/α-MSH expressie remt via activatie van de growth hormone 
secretagogue (GHS) receptor, vroegen we ons af of ghrelin effect zou kunnen hebben op 
insuline gevoeligheid via deze GHS receptor. Om onze hypothese te staven, hebben we 
vehicle, ghrelin en growth hormone releasing peptide 6 (GHRP-6, een specifieke agonist van 
de GHS receptor) intraveneus toegediend in wildtype muizen en insuline gevoeligheid 
gemeten (hoofstuk 7). Tot voor kort werd geloofd dat acylatie van serine-3 van het ghrelin 
molecuul noodzakelijk zou zijn voor bioactiviteit. Recente data suggereren echter dat des-
ghrelin ghrelin kan tegenwerken in de controle van de energie balans (5), en in vitro 
experimenten laten tegengestelde effecten van ghrelin en des-ghrelin op glucose productie 
in hepatocyten zien (6). Om de rol van des-ghrelin in de regulatie van energie fluxen verder 
te onderzoeken, hebben we de effecten van dit peptide in dezelfde context onderzocht. 
Totale en lever-specifieke insuline gevoeligheid werden gemeten met behulp van een 
hyperinsulinemische euglycemische clamp, in combinatie met D-[14C]glucose infusie. 
Weefsel specifieke insuline gevoeligheid werd gemeten met behulp van 2-deoxy-D[3H] 
glucose infusie. Hyperinsulinemie onderdrukte de endogene glucose productie significant 
minder in muizen die ghrelin kregen dan in de controles (controle: 71±11 %, ghrelin: 46±22 
%, GHRP-6: 70±22 %; p<0.05). In tegenstelling, de glucose opname snelheid was significant 
hoger in de dieren die ghrelin ontvingen ten opzichte van de controle groep (controle: 59±8 
µmol/kg/hour, ghrelin: 77±16 µmol/kg/hour, GHRP-6: 60±9 µmol/kg/hour; p<0.05), wat in 
overeenstemming was met de insuline gemedieerde 2-DG opname in spier en vetweefsel, 
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welke hoger was in de met ghrelin behandelde dieren vergeleken met de controle groep 
(spier: control: 8.6 ± 4.4; ghrelin: 26 ± 21; GHRP-6: 7.1 ± 3.4 µmol/g weefsel, p<0.05), 
hoewel dit niet statistisch significant was in vetweefsel (vetweefsel: controle: 2.6 ± 1.7; 
ghrelin: 7.9 ± 11; GHRP-6: 3.6 ± 1.5 µmol/g weefsel, p=0.09). Met betrekking tot des-ghrelin 
was, gedurende de hyperinsulinemisch periode, de insuline gestimuleerde glucose opname 
en de weefsel specifieke glucose opname niet verschillend van de controle groep. 
Hyperinsulinemie onderdrukte, in tegenstelling, de hepatische glucose productie significant 
minder in dieren die des-ghrelin kregen dan in de controle dieren (47±13 versus 71±11 %, 
p<0.01). Uit deze studie kunnen we concluderen dat ghrelin differentiele effecten heeft op 
weefsel-specifieke insuline actie, namelijk het verminderen van het vermogen om de 
endogene glucose productie te remmen, terwijl het de impact op de glucose opname 
versterkt. Deze effecten komen acuut voor en zijn niet secundair aan ghrelin’s bekende 
effecten op voedselinname en lichaamsgewicht. De GHS receptor is waarschijnlijk niet de 
mediair van de metabole effecten van ghrelin. Des-ghrelin lijkt ook energie fluxen te 
moduleren en kan ghrelin tegenwerken tijdens de controle van het glucose metabolisme. 
 
Conclusies 
De nucleus arcuatus in de hypothalamus speelt een centrale rol in de regulatie van eetlust 
en voedselinname. Tijdens vasten veranderen de expressies van neuropeptiden in de 
nucleus arcuatus die betrokken zijn bij de regulatie van voedselinname: expressie van het 
eetluststimulerende neuropeptide NPY stijgt, terwijl de expressie van het eetlustremmende 
neuropeptide POMC daalt, wat resulteert in de stimulatie van voedselinname. In gevoede 
toestand stijgt de expressie van POMC en daalt de expressie van NPY, wat resulteert in 
remming van voedselinname. 
 Recente studies laten zien dat de hersenen de eetlust en voedselinname regulerene in 
samenspraak met het maagdarmstelsel. De uitscheiding van gastrointestinale hormonen in 
het bloed varieert afhankelijk van voedingsstatus. Tijdens vasten stijgt de uitscheiding van 
ghrelin, een activator van NPY neuronen en een remmer van POMC neuronen, terwijl de 
uitscheiding van PYY3-36, een agonist van de presynaptische  NPY Y2 receptor en daardoor 
een remmer van NPY neuronen en activator van POMC neuronen, vermindert, wat resulteert 
in een verhoogde voedselinname. In gevoede toestand worden tegenovergestelde effecten 
gezien. 
 Tot voor kort werd gedacht dat de regulatie van het glucose metabolisme het resultaat 
was van de samenspraak tussen lever, spier en vetweefsel met de alvleesklier en bijnieren, 
die glucoregulatoire hormonen produceren, met een hoofdrol voor insuline. Recente studies 
echter veranderden deze ‘perifere’ blik naar een meer ‘centraal’ concept met een prominente 
rol voor de hersenen die de glucose homeostase reguleren. Recente studies van Rossetti et 
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al laten zien, dat chronische blokkade van insuline receptor signalen in de hypothalamus 
resulteert in hepatische insuline resistentie van de glucose productie, terwijl bij acute 
verwijdering van insuline receptoren in de lever het effect van fysiologische hyperinsulinemie 
op de snelheid van de glucose productie niet verandert (7-9). Deze studies laten zien dat 
insuline actie in de hersenen noodzakelijk is voor een intacte glucose homeostase. 
 De studies die uitgevoerd zijn binnen dit proefschrift laten zien dat de hersenen niet alleen 
voedselinname reguleren, maar ook insuline gevoeligheid van het glucose metabolisme in de 
lever en perifere weefsels, zoals spier en vetweefsel (zie figuur 1), afhankelijk en 
onafhankelijk van voedingsstatus en waarschijnlijk via gerelateerde veranderingen in 
gastrointestinale hormonen. Op deze manier kan op ieder moment de weefsel-specifieke 
insuline gevoeligheid nauwkeurig worden gereguleerd, afhankelijk en onafhankelijk van 
voedingsstatus.  
 We hebben laten zien, dat vasten zelf resulteert in een verhoging van de spier-specifieke 
insuline gevoeligheid. Aangezien intraveneuze toediening van ghrelin in muizen ook een 
verhoogde spier-specifieke insuline gevoeligheid liet zien, kan worden gespeculeerd dat de 
effecten van vasten op de perifere insuline gevoeligheid gemedieerd worden door een 
verhoogde secretie van ghrelin, waarschijnlijk (gedeeltelijk) in samenspraak met de 
NPY/POMC neuronale circuits in de nucleus arcuatus. Interessant genoeg laten alle 
interventie studies, uitgevoerd door anderen en in dit proefschrift, weefsel-specifieke effecten 
van de verschillende interventies op insuline gevoeligheid zien. Van den Hoek et al lieten 
zien dat centrale infusie van NPY de insuline actie op hepatische glucose productie 
verminderde, zonder effecten op perifere insuline gevoeligheid (10). Centrale injecties van 
MTII (stimuleert het POMC pad), resulteerden in een verhoging van de perifere glucose 
opname zonder effect op hepatische insuline gevoeligheid. Intraveneuze toediening van 
ghrelin verhoogde de perifere insuline gevoeligheid, maar verlaagde de lever-specifieke 
insuline gevoeligheid. Intraveneuze infusie van PYY3-36 verhoogde de perifere insuline 
gevoeligheid maar had geen effect op hepatische insuline gevoeligheid. 
 Aangezien, bijvoorbeeld, vasten en ghrelin de perifere insuline gevoeligheid verhogen, 
terwijl NPY, dat ook geactiveerd wordt door vasten, geen effect heeft op perifere insuline 
gevoeligheid, maar hepatische insuline resistentie veroorzaakt, kunnen de effecten van 
vasten en ghrelin op de perifere gevoeligheid niet slechts verklaard worden door de 
modulatie van NPY neuronen. Echter, de inductie van hepatische insuline resistentie door 
ghrelin zou (gedeeltelijk) het resultaat kunnen zijn van de activatie van NPY neuronen door 
ghrelin. 
 Hoewel anderen hebben laten zien dat de regulatie van voedselinname door 
gastrointestinale hormonen wordt gemedieerd door de hersenen, blijft dit speculatief voor de 
regulatie van insuline gevoeligheid in het lichaam. Receptoren van gastrointestinale 
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hormonen zijn overal in het lichaam te vinden, zowel centraal als perifeer. Uit de studies in 
dit proefschrift kunnen bovendien geen conclusies getrokken worden over de plaats van 
actie van gastrointestinale hormonen in het centrale zenuwstelsel. Er is meer onderzoek 
nodig, zoals perifere en centrale toediening van gastrointestinale hormonen in combinatie 
met blokkers van het NPY/POMC systeem en denervatie studies, om conclusies te trekken 
over de bijdrage van de hersenen en de plaats van actie in de hersenen met betrekking tot 
de regulatie van insuline gevoeligheid door veranderingen in concentraties gastrointestinale 
hormonen. 
 Aangezien glucose onontbeerlijk is als energiebron voor de hersenen, is de regulatie van 
voedselinname en insuline gevoeligheid van het grootst mogelijk belang voor de hersenen. 
Het is daarom niet verwonderlijk dat de hersenen zelf betrokken zijn bij de uiterst 
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